1
|
Araki M, Park SJ, Dauerman HL, Uemura S, Kim JS, Di Mario C, Johnson TW, Guagliumi G, Kastrati A, Joner M, Holm NR, Alfonso F, Wijns W, Adriaenssens T, Nef H, Rioufol G, Amabile N, Souteyrand G, Meneveau N, Gerbaud E, Opolski MP, Gonzalo N, Tearney GJ, Bouma B, Aguirre AD, Mintz GS, Stone GW, Bourantas CV, Räber L, Gili S, Mizuno K, Kimura S, Shinke T, Hong MK, Jang Y, Cho JM, Yan BP, Porto I, Niccoli G, Montone RA, Thondapu V, Papafaklis MI, Michalis LK, Reynolds H, Saw J, Libby P, Weisz G, Iannaccone M, Gori T, Toutouzas K, Yonetsu T, Minami Y, Takano M, Raffel OC, Kurihara O, Soeda T, Sugiyama T, Kim HO, Lee T, Higuma T, Nakajima A, Yamamoto E, Bryniarski KL, Di Vito L, Vergallo R, Fracassi F, Russo M, Seegers LM, McNulty I, Park S, Feldman M, Escaned J, Prati F, Arbustini E, Pinto FJ, Waksman R, Garcia-Garcia HM, Maehara A, Ali Z, Finn AV, Virmani R, Kini AS, Daemen J, Kume T, Hibi K, Tanaka A, Akasaka T, Kubo T, Yasuda S, Croce K, Granada JF, Lerman A, Prasad A, Regar E, Saito Y, Sankardas MA, Subban V, Weissman NJ, Chen Y, Yu B, Nicholls SJ, Barlis P, West NEJ, Arbab-Zadeh A, Ye JC, Dijkstra J, Lee H, Narula J, Crea F, Nakamura S, Kakuta T, Fujimoto J, Fuster V, Jang IK. Author Correction: Optical coherence tomography in coronary atherosclerosis assessment and intervention. Nat Rev Cardiol 2024; 21:348. [PMID: 38110566 DOI: 10.1038/s41569-023-00982-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2023]
Affiliation(s)
| | | | | | | | - Jung-Sun Kim
- Yonsei University College of Medicine, Seoul, South Korea
| | | | - Thomas W Johnson
- University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
| | | | - Adnan Kastrati
- Technische Universität München and Munich Heart Alliance, Munich, Germany
| | | | | | | | - William Wijns
- National University of Ireland Galway and Saolta University Healthcare Group, Galway, Ireland
| | | | | | - Gilles Rioufol
- Hospices Civils de Lyon and Claude Bernard University, Lyon, France
| | | | | | | | | | | | - Nieves Gonzalo
- Hospital Clinico San Carlos, IdISSC, Universidad Complutense, Madrid, Spain
| | | | - Brett Bouma
- Massachusetts General Hospital, Boston, MA, USA
| | | | - Gary S Mintz
- Cardiovascular Research Foundation, New York, NY, USA
| | - Gregg W Stone
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Christos V Bourantas
- Barts Health NHS Trust, University College London and Queen Mary University London, London, UK
| | - Lorenz Räber
- Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | | | | | | | | | - Myeong-Ki Hong
- Yonsei University College of Medicine, Seoul, South Korea
| | - Yangsoo Jang
- Yonsei University College of Medicine, Seoul, South Korea
| | | | - Bryan P Yan
- Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Italo Porto
- University of Genoa, Genoa, Italy, San Martino Hospital, IRCCS for Oncology and Neurosciences, Genoa, Italy
| | | | - Rocco A Montone
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | | | | | | | - Harmony Reynolds
- New York University Grossman School of Medicine, New York, NY, USA
| | - Jacqueline Saw
- Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
| | - Peter Libby
- Brigham and Women's Hospital, Boston, MA, USA
| | - Giora Weisz
- New York Presbyterian Hospital, Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY, USA
| | | | - Tommaso Gori
- Universitäts medizin Mainz and DZHK Rhein-Main, Mainz, Germany
| | | | | | | | | | | | - Osamu Kurihara
- Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan
| | | | | | | | - Tetsumin Lee
- Japanese Red Cross Musashino Hospital, Tokyo, Japan
| | - Takumi Higuma
- Kawasaki Municipal Tama Hospital, St. Marianna University School of Medicine, Kanagawa, Japan
| | | | - Erika Yamamoto
- Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Krzysztof L Bryniarski
- Jagiellonian University Medical College, Institute of Cardiology, Department of Interventional Cardiology, John Paul II Hospital, Krakow, Poland
| | | | | | | | - Michele Russo
- Catholic University of the Sacred Heart, Rome, Italy
| | | | | | - Sangjoon Park
- Korea Advanced Institute of Science and Technology, Daejeon, South Korea
| | - Marc Feldman
- University of Texas Health, San Antonio, TX, USA
| | | | - Francesco Prati
- UniCamillus - Saint Camillus International University of Health Sciences, Rome, Italy
| | - Eloisa Arbustini
- IRCCS Foundation University Hospital Policlinico San Matteo, Pavia, Italy
| | - Fausto J Pinto
- Santa Maria University Hospital, CHULN Center of Cardiology of the University of Lisbon, Lisbon School of Medicine, Lisbon Academic Medical Center, Lisbon, Portugal
| | - Ron Waksman
- MedStar Washington Hospital Center, Washington, DC, USA
| | | | - Akiko Maehara
- Cardiovascular Research Foundation, New York, NY, USA
| | - Ziad Ali
- Cardiovascular Research Foundation, New York, NY, USA
| | | | | | | | - Joost Daemen
- Erasmus University Medical Centre, Rotterdam, Netherlands
| | | | - Kiyoshi Hibi
- Yokohama City University Medical Center, Kanagawa, Japan
| | | | | | | | - Satoshi Yasuda
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Kevin Croce
- Brigham and Women's Hospital, Boston, MA, USA
| | | | | | | | | | | | | | | | | | - Yundai Chen
- Sixth Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Bo Yu
- The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | | | - Peter Barlis
- University of Melbourne, Melbourne, Victoria, Australia
| | | | | | - Jong Chul Ye
- Korea Advanced Institute of Science and Technology, Daejeon, South Korea
| | | | - Hang Lee
- Massachusetts General Hospital, Boston, MA, USA
| | - Jagat Narula
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Filippo Crea
- Catholic University of the Sacred Heart, Rome, Italy
| | | | | | - James Fujimoto
- Massachusetts Institute of Technology, Cambridge, MA, USA
| | | | - Ik-Kyung Jang
- Massachusetts General Hospital, Boston, MA, USA.
- Kyung Hee University, Seoul, South Korea.
| |
Collapse
|
2
|
Boeckling F, Stähli BE, Rudolph T, Lutz M, Schatz AS, Vogelmann T, Stueve M, West NEJ, Boone E, Erbay A, Leistner DM. Fractional flow reserve measurements and long-term mortality-results from the FLORIDA study. Front Cardiovasc Med 2024; 11:1337941. [PMID: 38404721 PMCID: PMC10885355 DOI: 10.3389/fcvm.2024.1337941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Accepted: 01/29/2024] [Indexed: 02/27/2024] Open
Abstract
Background Randomized evidence suggested improved outcomes in fractional flow reserve (FFR) guidance of coronary revascularization compared to medical therapy in well-defined patient cohorts. However, the impact of FFR-guided revascularization on long-term outcomes of unselected patients with chronic or acute coronary syndromes (ACS) is unknown. Aims The FLORIDA (Fractional FLOw Reserve In cardiovascular DiseAses) study sought to investigate outcomes of FFR-guided vs. angiography-guided treatment strategies in a large, real-world cohort. Methods This study included patients enrolled into the German InGef Research Database. Patients undergoing coronary angiography between January 2014 and December 2015 were included in the analysis. Eligible patients had at least one inpatient coronary angiogram for suspected coronary artery disease between January 2014 and December 2015. Patients were stratified into FFR arm if a coronary angiography with adjunctive FFR measurement was performed, otherwise into the angiography-only arm. Matching was applied to ensure a balanced distribution of baseline characteristics in the study cohort. Patients were followed for 3 years after index date and primary endpoint was all-cause mortality. Results In the matched population, mortality at 3 years was 9.6% in the FFR-assessed group and 12.6% in the angiography-only group (p = 0.002), corresponding to a 24% relative risk reduction with use of FFR. This effect was most pronounced in patients in whom revascularization was deferred based on FFR (8.7% vs. 12.3%, p = 0.04) and in high-risk subgroups including patients aged ≥75 years (14.9% vs. 20.1%, p < 0.01) and those presenting with ACS (10.2% vs. 14.0%, p = 0.04). Conclusions FFR-based revascularization strategy was associated with reduced mortality at 3 years. These findings further support the use of FFR in everyday clinical practice.
Collapse
Affiliation(s)
- Felicitas Boeckling
- Department of Medicine, Cardiology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - Barbara E. Stähli
- Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
| | - Tanja Rudolph
- Department for General and Interventional Cardiology/Angiology, Heart- und Diabetes Center NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany
| | - Matthias Lutz
- Department of Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany
| | - Anne-Sophie Schatz
- Department of Cardiology, Charité—University Medicine Berlin, Berlin, Germany
| | | | | | | | - Els Boone
- Abbott Vascular, Santa Clara, CA, United States
| | - Aslihan Erbay
- Department of Medicine, Cardiology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| | - David M. Leistner
- Department of Medicine, Cardiology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany
| |
Collapse
|
3
|
Narang M, Saxena A, Kaur R, Gopa HR, West NEJ. Variability in research culture across busy catheterisation labs in the Asia-Pacific region. AsiaIntervention 2024; 10:26-33. [PMID: 38425813 PMCID: PMC10900241 DOI: 10.4244/aij-d-23-00005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Accepted: 07/11/2023] [Indexed: 03/02/2024]
Abstract
Background Information related to research culture in the busy catheterisation (cath) labs across the Asia-Pacific (APAC) region is sparse. Aims The aims of this study were to examine the variability in research culture in busy cath labs in the APAC region and to propose a roadmap for hospitals to develop in-house research capabilities in conjunction with industry and academia. Methods Data related to research practices in the APAC region were collected from busy cath labs (at least 250 angioplasty/year) and analysed. Results were shared with research experts to understand the challenges in institutional research and create a roadmap for hospitals to develop research capabilities. Results A total of 220 respondents from 62 cath labs (88.6%) across 13 APAC countries participated in the survey. A wide variation was noted in research culture across APAC countries. Well-established infrastructure was reported in Australia, New Zealand, South Korea, Singapore, and Japan. Large multicentre trials were common in South Korea, while routine follow-ups were common in Japan. Linking medical records across hospitals/states was considered challenging. Research exposure and training were limited in the APAC region. The experts suggested a roadmap, including creating a conducive regulatory environment, forming synergistic goals, training programs for the professionals involved in research, and leveraging best practices, for improving the research culture in APAC. Conclusions Clinical research in cardiology has grown significantly in the APAC region, with a huge research potential in China and India. Implementing measures to improve research training and involvement of the industry will boost the research culture in the APAC region.
Collapse
Affiliation(s)
- Manish Narang
- Department of Medical Affairs, Abbott Vascular, Abbott Healthcare Pvt Ltd, New Delhi, India
| | - Aseem Saxena
- Department of Medical Affairs, Abbott Vascular, Abbott Healthcare Pvt Ltd, New Delhi, India
| | - Ramneek Kaur
- Department of Medical Affairs, Abbott Vascular, Abbott Healthcare Pvt Ltd, New Delhi, India
| | | | - Nick E J West
- Global Medical Affairs, Abbott Vascular, Santa Clara, CA, USA
| |
Collapse
|
4
|
Secemsky EA, Kirksey L, Quiroga E, King CM, Martinson M, Hasegawa JT, West NEJ, Wadhera RK. Impact of Intensity of Vascular Care Preceding Major Amputation Among Patients With Chronic Limb-Threatening Ischemia. Circ Cardiovasc Interv 2024; 17:e012798. [PMID: 38152880 DOI: 10.1161/circinterventions.122.012798] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 09/22/2023] [Indexed: 12/29/2023]
Abstract
BACKGROUND Lower-limb amputation rates in patients with chronic limb-threatening ischemia vary across the United States, with marked disparities in amputation rates by gender, race, and income status. We evaluated the association of patient, hospital, and geographic characteristics with the intensity of vascular care received the year before a major lower-limb amputation and how intensity of care associates with outcomes after amputation. METHODS Using Medicare claims data (2016-2019), beneficiaries diagnosed with chronic limb-threatening ischemia who underwent a major lower-limb amputation were identified. We examined patient, hospital, and geographic characteristics associated with the intensity of vascular care received the year before amputation. Secondary objectives evaluated all-cause mortality and adverse events following amputation. RESULTS Of 33 036 total Medicare beneficiaries undergoing major amputation, 7885 (23.9%) were due to chronic limb-threatening ischemia; of these, 4988 (63.3%) received low-intensity and 2897 (36.7%) received high-intensity vascular care. Mean age, 76.6 years; women, 38.9%; Black adults, 24.5%; and of low income, 35.2%. After multivariable adjustment, those of low income (odds ratio, 0.65 [95% CI, 0.58-0.72]; P<0.001), and to a lesser extent, men (odds ratio, 0.89 [95% CI, 0.81-0.98]; P=0.019), and those who received care at a safety-net hospital (odds ratio, 0.87 [95% CI, 0.78-0.97]; P=0.012) were most likely to receive low intensity of care before amputation. High-intensity care was associated with a lower risk of all-cause mortality 2 years following amputation (hazard ratio, 0.79 [95% CI, 0.74-0.85]; P<0.001). CONCLUSIONS Patients who were of low-income status, and to a lesser extent, men, or those cared for at safety-net hospitals were most likely to receive low-intensity vascular care. Low-intensity care was associated with worse long-term event-free survival. These data emphasize the continued disparities that exist in contemporary vascular practice.
Collapse
Affiliation(s)
- Eric A Secemsky
- Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (E.A.S., R.K.W.)
| | - Lee Kirksey
- Department of Vascular Surgery, Cleveland Clinic, OH (L.K.)
| | - Elina Quiroga
- Division of Vascular Surgery, Department of Surgery, University of Washington, Seattle (E.Q.)
| | - Claire M King
- Abbott Vascular, Santa Clara, CA (C.M.K., J.T.H., N.E.J.W.)
| | | | | | - Nick E J West
- Abbott Vascular, Santa Clara, CA (C.M.K., J.T.H., N.E.J.W.)
| | - Rishi K Wadhera
- Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (E.A.S., R.K.W.)
| |
Collapse
|
5
|
Munhoz D, Collet C, Mizukami T, Yong A, Leone AM, Eftekhari A, Ko B, da Costa BR, Berry C, Collison D, Perera D, Christiansen EH, Rivero F, Zimmermann FM, Ando H, Matsuo H, Nakayama M, Escaned J, Sonck J, Sakai K, Adjedj J, Desta L, van Nunen LX, West NEJ, Fournier S, Storozhenko T, Amano T, Engstrøm T, Johnson T, Shinke T, Biscaglia S, Fearon WF, Ali Z, De Bruyne B, Johnson NP. Rationale and design of the pullback pressure gradient (PPG) global registry. Am Heart J 2023; 265:170-179. [PMID: 37611857 DOI: 10.1016/j.ahj.2023.07.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 06/20/2023] [Accepted: 07/08/2023] [Indexed: 08/25/2023]
Abstract
INTRODUCTION Diffuse disease has been identified as one of the main reasons leading to low post-PCI fractional flow reserve (FFR) and residual angina after PCI. Coronary pressure pullbacks allow for the evaluation of hemodynamic coronary artery disease (CAD) patterns. The pullback pressure gradient (PPG) is a novel metric that quantifies the distribution and magnitude of pressure losses along the coronary artery in a focal-to-diffuse continuum. AIM The primary objective is to determine the predictive capacity of the PPG for post-PCI FFR. METHODS This prospective, large-scale, controlled, investigator-initiated, multicenter study is enrolling patients with at least 1 lesion in a major epicardial vessel with a distal FFR ≤ 0.80 intended to be treated by PCI. The study will include 982 subjects. A standardized physiological assessment will be performed pre-PCI, including the online calculation of PPG from FFR pullbacks performed manually. PPG quantifies the CAD pattern by combining several parameters from the FFR pullback curve. Post-PCI physiology will be recorded using a standardized protocol with FFR pullbacks. We hypothesize that PPG will predict optimal PCI results (post-PCI FFR ≥ 0.88) with an area under the ROC curve (AUC) ≥ 0.80. Secondary objectives include patient-reported and clinical outcomes in patients with focal vs. diffuse CAD defined by the PPG. Clinical follow-up will be collected for up to 36 months, and an independent clinical event committee will adjudicate events. RESULTS Recruitment is ongoing and is expected to be completed in the second half of 2023. CONCLUSION This international, large-scale, prospective study with pre-specified powered hypotheses will determine the ability of the preprocedural PPG index to predict optimal revascularization assessed by post-PCI FFR. In addition, it will evaluate the impact of PPG on treatment decisions and the predictive performance of PPG for angina relief and clinical outcomes.
Collapse
Affiliation(s)
- Daniel Munhoz
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy
| | - Carlos Collet
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium
| | - Takuya Mizukami
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Division of Clinical Pharmacology, Department of Pharmacology, Showa University, Tokyo, Japan
| | - Andy Yong
- Concord Repatriation General Hospital, University of Sydney, New South Wales, Australia
| | - Antonio Maria Leone
- Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University School of Medicine, Rome, Italy; Center of Excellence in Cardiovascular Diagnostics and Therapeutic, Ospedale Fabenefratelli Isola Tiberina Gemelli Isola, Rome, Italy
| | - Ashkan Eftekhari
- Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark
| | - Brian Ko
- Monash Cardiovascular Research Centre, Monash University and Monash Heart, Monash Health, Clayton, Victoria, Australia
| | - Bruno R da Costa
- Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, England; Clinical Epidemiology and Health Care Research, Institute of Health Policy and Management Evaluation (IHPME), University of Toronto, Toronto, Ontorio, Canada
| | - Colin Berry
- School Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK
| | - Damien Collison
- School Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK
| | - Divaka Perera
- School of Cardiovascular Medicine and Sciences, St Thomas' Hospital Campus, King's College London, London, UK
| | | | - Fernando Rivero
- Cardiac Department, Hospital Universitario de La Princesa, Madrid, Spain
| | | | - Hirohiko Ando
- Department of Cardiology, Aichi Medical University, Aichi, Japan
| | - Hitoshi Matsuo
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| | | | - Javier Escaned
- Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos and Complutense University, Madrid, Spain
| | - Jeroen Sonck
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium
| | - Koshiro Sakai
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan
| | - Julien Adjedj
- Department of Cardiology, Arnault Tzanck Institute Saint Laurent du Var, France
| | - Liyew Desta
- Department of Cardiology, Karolinska University Hospital, Solna, Stockholm, Sweden
| | - Lokien X van Nunen
- Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands
| | | | - Stephane Fournier
- Department of Cardiology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Tatyana Storozhenko
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Prevention and Treatment of Emergency Conditions, L.T. Malaya Therapy National Institute NAMSU, Kharkiv, Ukraine
| | - Tetsuya Amano
- Department of Cardiology, Aichi Medical University, Aichi, Japan
| | - Thomas Engstrøm
- Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Thomas Johnson
- University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, United Kingdom
| | - Toshiro Shinke
- Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan
| | - Simone Biscaglia
- Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy
| | - William F Fearon
- Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University School of Medicine and VA Palo Alto Health Care System, Palo Alto, CA
| | - Ziad Ali
- St Francis Hospital and Heart Center, Roslyn, NY
| | - Bernard De Bruyne
- Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Cardiology, University Hospital of Lausanne, Lausanne, Switzerland
| | - Nils P Johnson
- Weatherhead PET Center, Division of Cardiology, Department of Medicine, McGovern Medical School at UTHealth and Memorial Hermann Hospital, Houston, TX.
| |
Collapse
|
6
|
Samant S, Bakhos JJ, Wu W, Zhao S, Kassab GS, Khan B, Panagopoulos A, Makadia J, Oguz UM, Banga A, Fayaz M, Glass W, Chiastra C, Burzotta F, LaDisa JF, Iaizzo P, Murasato Y, Dubini G, Migliavacca F, Mickley T, Bicek A, Fontana J, West NEJ, Mortier P, Boyers PJ, Gold JP, Anderson DR, Tcheng JE, Windle JR, Samady H, Jaffer FA, Desai NR, Lansky A, Mena-Hurtado C, Abbott D, Brilakis ES, Lassen JF, Louvard Y, Stankovic G, Serruys PW, Velazquez E, Elias P, Bhatt DL, Dangas G, Chatzizisis YS. Artificial Intelligence, Computational Simulations, and Extended Reality in Cardiovascular Interventions. JACC Cardiovasc Interv 2023; 16:2479-2497. [PMID: 37879802 DOI: 10.1016/j.jcin.2023.07.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Revised: 07/11/2023] [Accepted: 07/13/2023] [Indexed: 10/27/2023]
Abstract
Artificial intelligence, computational simulations, and extended reality, among other 21st century computational technologies, are changing the health care system. To collectively highlight the most recent advances and benefits of artificial intelligence, computational simulations, and extended reality in cardiovascular therapies, we coined the abbreviation AISER. The review particularly focuses on the following applications of AISER: 1) preprocedural planning and clinical decision making; 2) virtual clinical trials, and cardiovascular device research, development, and regulatory approval; and 3) education and training of interventional health care professionals and medical technology innovators. We also discuss the obstacles and constraints associated with the application of AISER technologies, as well as the proposed solutions. Interventional health care professionals, computer scientists, biomedical engineers, experts in bioinformatics and visualization, the device industry, ethics committees, and regulatory agencies are expected to streamline the use of AISER technologies in cardiovascular interventions and medicine in general.
Collapse
Affiliation(s)
- Saurabhi Samant
- Center for Digital Cardiovascular Innovations, Division of Cardiovascular Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA; Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Jules Joel Bakhos
- Center for Digital Cardiovascular Innovations, Division of Cardiovascular Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA; Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Wei Wu
- Center for Digital Cardiovascular Innovations, Division of Cardiovascular Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA; Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Shijia Zhao
- Center for Digital Cardiovascular Innovations, Division of Cardiovascular Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA; Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Ghassan S Kassab
- California Medical Innovations Institute, San Diego, California, USA
| | - Behram Khan
- Center for Digital Cardiovascular Innovations, Division of Cardiovascular Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA; Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Anastasios Panagopoulos
- Center for Digital Cardiovascular Innovations, Division of Cardiovascular Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA; Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Janaki Makadia
- Center for Digital Cardiovascular Innovations, Division of Cardiovascular Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA; Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Usama M Oguz
- Center for Digital Cardiovascular Innovations, Division of Cardiovascular Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA; Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Akshat Banga
- Center for Digital Cardiovascular Innovations, Division of Cardiovascular Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA; Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Muhammad Fayaz
- Center for Digital Cardiovascular Innovations, Division of Cardiovascular Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA; Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - William Glass
- Interprofessional Experiential Center for Enduring Learning, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Claudio Chiastra
- PoliTo(BIO)Med Lab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Turin, Italy
| | - Francesco Burzotta
- Department of Cardiovascular Sciences, Università Cattolica Del Sacro Cuore, Rome, Italy
| | - John F LaDisa
- Departments of Biomedical Engineering and Pediatrics - Division of Cardiology, Herma Heart Institute, Children's Wisconsin and the Medical College of Wisconsin, and the MARquette Visualization Lab, Marquette University, Milwaukee, Wisconsin, USA
| | - Paul Iaizzo
- Visible Heart Laboratories, Department of Surgery, University of Minnesota, Minnesota, USA
| | - Yoshinobu Murasato
- Department of Cardiology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - Gabriele Dubini
- Department of Chemistry, Materials and Chemical Engineering 'Giulio Natta', Politecnico di Milano, Milan, Italy
| | - Francesco Migliavacca
- Department of Chemistry, Materials and Chemical Engineering 'Giulio Natta', Politecnico di Milano, Milan, Italy
| | | | - Andrew Bicek
- Boston Scientific Inc, Marlborough, Massachusetts, USA
| | | | | | | | - Pamela J Boyers
- Interprofessional Experiential Center for Enduring Learning, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Jeffrey P Gold
- Interprofessional Experiential Center for Enduring Learning, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Daniel R Anderson
- Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - James E Tcheng
- Cardiovascular Division, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
| | - John R Windle
- Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Habib Samady
- Georgia Heart Institute, Gainesville, Georgia, USA
| | - Farouc A Jaffer
- Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Nihar R Desai
- Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA
| | - Alexandra Lansky
- Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA
| | - Carlos Mena-Hurtado
- Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA
| | - Dawn Abbott
- Cardiovascular Institute, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA
| | - Emmanouil S Brilakis
- Center for Advanced Coronary Interventions, Minneapolis Heart Institute, Minneapolis, Minnesota, USA
| | - Jens Flensted Lassen
- Department of Cardiology B, Odense University Hospital, Odense, Syddanmark, Denmark
| | - Yves Louvard
- Institut Cardiovasculaire Paris Sud, Massy, France
| | - Goran Stankovic
- Department of Cardiology, Clinical Center of Serbia, Belgrade, Serbia
| | - Patrick W Serruys
- Department of Cardiology, National University of Ireland, Galway, Galway, Ireland
| | - Eric Velazquez
- Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut, USA
| | - Pierre Elias
- Seymour, Paul, and Gloria Milstein Division of Cardiology, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York, USA
| | - Deepak L Bhatt
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - George Dangas
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Yiannis S Chatzizisis
- Center for Digital Cardiovascular Innovations, Division of Cardiovascular Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA; Cardiovascular Biology and Biomechanics Laboratory (CBBL), Cardiovascular Division, University of Nebraska Medical Center, Omaha, Nebraska, USA.
| |
Collapse
|
7
|
Ali ZA, Landmesser U, Maehara A, Matsumura M, Shlofmitz RA, Guagliumi G, Price MJ, Hill JM, Akasaka T, Prati F, Bezerra HG, Wijns W, Leistner D, Canova P, Alfonso F, Fabbiocchi F, Dogan O, McGreevy RJ, McNutt RW, Nie H, Buccola J, West NEJ, Stone GW. Optical Coherence Tomography-Guided versus Angiography-Guided PCI. N Engl J Med 2023; 389:1466-1476. [PMID: 37634188 DOI: 10.1056/nejmoa2305861] [Citation(s) in RCA: 28] [Impact Index Per Article: 28.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/29/2023]
Abstract
BACKGROUND Data regarding clinical outcomes after optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) as compared with angiography-guided PCI are limited. METHODS In this prospective, randomized, single-blind trial, we randomly assigned patients with medication-treated diabetes or complex coronary-artery lesions to undergo OCT-guided PCI or angiography-guided PCI. A final blinded OCT procedure was performed in patients in the angiography group. The two primary efficacy end points were the minimum stent area after PCI as assessed with OCT and target-vessel failure at 2 years, defined as a composite of death from cardiac causes, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization. Safety was also assessed. RESULTS The trial was conducted at 80 sites in 18 countries. A total of 2487 patients underwent randomization: 1233 patients were assigned to undergo OCT-guided PCI, and 1254 to undergo angiography-guided PCI. The minimum stent area after PCI was 5.72±2.04 mm2 in the OCT group and 5.36±1.87 mm2 in the angiography group (mean difference, 0.36 mm2; 95% confidence interval [CI], 0.21 to 0.51; P<0.001). Target-vessel failure within 2 years occurred in 88 patients in the OCT group and in 99 patients in the angiography group (Kaplan-Meier estimates, 7.4% and 8.2%, respectively; hazard ratio, 0.90; 95% CI, 0.67 to 1.19; P = 0.45). OCT-related adverse events occurred in 1 patient in the OCT group and in 2 patients in the angiography group. Stent thrombosis within 2 years occurred in 6 patients (0.5%) in the OCT group and in 17 patients (1.4%) in the angiography group. CONCLUSIONS Among patients undergoing PCI, OCT guidance resulted in a larger minimum stent area than angiography guidance, but there was no apparent between-group difference in the percentage of patients with target-vessel failure at 2 years. (Funded by Abbott; ILUMIEN IV: OPTIMAL PCI ClinicalTrials.gov number, NCT03507777.).
Collapse
Affiliation(s)
- Ziad A Ali
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Ulf Landmesser
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Akiko Maehara
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Mitsuaki Matsumura
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Richard A Shlofmitz
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Giulio Guagliumi
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Matthew J Price
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Jonathan M Hill
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Takashi Akasaka
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Francesco Prati
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Hiram G Bezerra
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - William Wijns
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - David Leistner
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Paolo Canova
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Fernando Alfonso
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Franco Fabbiocchi
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Ozgen Dogan
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Robert J McGreevy
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Robert W McNutt
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Hong Nie
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Jana Buccola
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Nick E J West
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| | - Gregg W Stone
- From St. Francis Hospital, Roslyn (Z.A.A., R.A.S.), Clinical Trials Center, Cardiovascular Research Foundation, New York (Z.A.A., A.M., M.M.), the Center for Interventional Cardiovascular Care, Columbia University (A.M., O.D.), and the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai (G.W.S.), New York, and New York Institute of Technology, Glen Head (Z.A.A.) - all in New York; the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin (U.L., D.L.), Berlin Institute of Health (U.L.), and Deutsches Zentrum für Herz-Kreislaufforschung (DZHK), Partner Site Berlin (U.L.), Berlin, and the Department of Medicine, Cardiology, Goethe University Hospital, and DZHK Partner Site Rhein-Main, Frankfurt (D.L.) - all in Germany; IRCCS Galeazzi Sant'Ambrogio Hospital (G.G.) and IRCCS Centro Cardiologico Monzino (F.F.), Milan, Saint Camillus International University of Health Sciences and Centro per la Lotta contro l'Infarto, Rome (F.P.), and Ospedale Papa Giovanni XXIII, Bergamo (P.C.) - all in Italy; the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla (M.J.P.), and Abbott Vascular, Santa Clara (R.J.M., R.W.M., H.N., J.B., N.E.J.W.) - both in California; Royal Brompton Hospital, London (J.M.H.); Wakayama Medical University, Wakayama, Japan (T.A.); Tampa General Hospital, Tampa, FL (H.G.B.); the Lambe Institute for Translational Medicine and Cúram, University of Galway, Galway, Ireland (W.W.); and the Department of Cardiology, Hospital Universitario de la Princesa, Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid (F.A.)
| |
Collapse
|
8
|
Collet C, Johnson NP, Mizukami T, Fearon WF, Berry C, Sonck J, Collison D, Koo BK, Meneveau N, Agarwal SK, Uretsky B, Hakeem A, Doh JH, Da Costa BR, Oldroyd KG, Leipsic JA, Morbiducci U, Taylor C, Ko B, Tonino PAL, Perera D, Shinke T, Chiastra C, Sposito AC, Leone AM, Muller O, Fournier S, Matsuo H, Adjedj J, Amabile N, Piróth Z, Alfonso F, Rivero F, Ahn JM, Toth GG, Ihdayhid A, West NEJ, Amano T, Wyffels E, Munhoz D, Belmonte M, Ohashi H, Sakai K, Gallinoro E, Barbato E, Engstrøm T, Escaned J, Ali ZA, Kern MJ, Pijls NHJ, Jüni P, De Bruyne B. Impact of Post-PCI FFR Stratified by Coronary Artery. JACC Cardiovasc Interv 2023; 16:2396-2408. [PMID: 37821185 DOI: 10.1016/j.jcin.2023.08.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Revised: 08/04/2023] [Accepted: 08/08/2023] [Indexed: 10/13/2023]
Abstract
BACKGROUND Low fractional flow reserve (FFR) after percutaneous coronary intervention (PCI) has been associated with adverse clinical outcomes. Hitherto, this assessment has been independent of the epicardial vessel interrogated. OBJECTIVES This study sought to assess the predictive capacity of post-PCI FFR for target vessel failure (TVF) stratified by coronary artery. METHODS We performed a systematic review and individual patient-level data meta-analysis of randomized clinical trials and observational studies with protocol-recommended post-PCI FFR assessment. The difference in post-PCI FFR between left anterior descending (LAD) and non-LAD arteries was assessed using a random-effect models meta-analysis of mean differences. TVF was defined as a composite of cardiac death, target vessel myocardial infarction, and clinically driven target vessel revascularization. RESULTS Overall, 3,336 vessels (n = 2,760 patients) with post-PCI FFR measurements were included in 9 studies. The weighted mean post-PCI FFR was 0.89 (95% CI: 0.87-0.90) and differed significantly between coronary vessels (LAD = 0.86; 95% CI: 0.85 to 0.88 vs non-LAD = 0.93; 95% CI: 0.91-0.94; P < 0.001). Post-PCI FFR was an independent predictor of TVF, with its risk increasing by 52% for every reduction of 0.10 FFR units, and this was mainly driven by TVR. The predictive capacity for TVF was poor for LAD arteries (AUC: 0.52; 95% CI: 0.47-0.58) and moderate for non-LAD arteries (AUC: 0.66; 95% CI: 0.59-0.73; LAD vs non-LAD arteries, P = 0.005). CONCLUSIONS The LAD is associated with a lower post-PCI FFR than non-LAD arteries, emphasizing the importance of interpreting post-PCI FFR on a vessel-specific basis. Although a higher post-PCI FFR was associated with improved prognosis, its predictive capacity for events differs between the LAD and non-LAD arteries, being poor in the LAD and moderate in the non-LAD vessels.
Collapse
Affiliation(s)
- Carlos Collet
- Cardiovascular Center Aalst, onze lieve vrouw Clinic, Aalst, Belgium.
| | - Nils P Johnson
- Division of Cardiology, Department of Medicine, McGovern Medical School at University of Texas Health and Memorial Hermann Hospital, Houston, Texas, USA
| | - Takuya Mizukami
- Cardiovascular Center Aalst, onze lieve vrouw Clinic, Aalst, Belgium; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan
| | - William F Fearon
- Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA
| | - Colin Berry
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom; West of Scotland Regional Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, Glasgow, United Kingdom
| | - Jeroen Sonck
- Cardiovascular Center Aalst, onze lieve vrouw Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy
| | - Damien Collison
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom; West of Scotland Regional Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, Glasgow, United Kingdom
| | - Bon-Kwon Koo
- Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, South Korea
| | - Nicolas Meneveau
- Department of Cardiology, University Hospital Jean Minjoz, Besançon, France; University of Burgundy Franche-Comté, Besançon, France
| | - Shiv Kumar Agarwal
- Division of Cardiology, Central Arkansas Veterans Health System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
| | - Barry Uretsky
- Division of Cardiology, Central Arkansas Veterans Health System, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
| | - Abdul Hakeem
- Division of Cardiovascular Diseases and Cardiovascular Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
| | - Joon-Hyung Doh
- Department of Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea
| | - Bruno R Da Costa
- Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Keith G Oldroyd
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom; West of Scotland Regional Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, Glasgow, United Kingdom
| | - Jonathon A Leipsic
- Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Umberto Morbiducci
- PolitoBIOMed Lab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Turin, Italy
| | | | - Brian Ko
- Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Victoria, Australia
| | - Pim A L Tonino
- Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands; Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Divaka Perera
- National Institute for Health Research Guy's and St Thomas' Biomedical Research Centre, King's College London and Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom
| | - Toshiro Shinke
- Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Claudio Chiastra
- PolitoBIOMed Lab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Turin, Italy
| | - Andrei C Sposito
- Department of Internal Medicine, Discipline of Cardiology, University of Campinas, Campinas, Brazil
| | - Antonio Maria Leone
- Center of Excellence in Cardiovascular Sciences, Ospedale Fatebenefratelli Isola Tiberina Gemelli Isola, Università Cattolica del Sacro Cuore, Roma, Italy
| | - Olivier Muller
- Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland
| | - Stephane Fournier
- Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland
| | - Hitoshi Matsuo
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| | - Julien Adjedj
- Department of Cardiology, Arnault Tzanck Institute Saint Laurent du Var, France
| | - Nicolas Amabile
- Department of Cardiology, Institut Mutualiste Montsouris, Paris, France
| | - Zsolt Piróth
- Gottsegen National Cardiovascular Center, Budapest, Hungary
| | - Fernando Alfonso
- Cardiology Department, Hospital Universitario de La Princesa, IIS-IP, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain
| | - Fernando Rivero
- Cardiology Department, Hospital Universitario de La Princesa, IIS-IP, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain
| | - Jung-Min Ahn
- Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Gabor G Toth
- Division of Cardiology, University Heart Center Graz, Medical University of Graz, Graz, Austria
| | - Abdul Ihdayhid
- Fiona Stanley Hospital, Harry Perkins Institute of Medical Research, Curtin University, Perth, Australia
| | | | - Tetsuya Amano
- Department of Cardiology, Aichi Medical University, Aichi, Japan
| | - Eric Wyffels
- Cardiovascular Center Aalst, onze lieve vrouw Clinic, Aalst, Belgium
| | - Daniel Munhoz
- Cardiovascular Center Aalst, onze lieve vrouw Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy; Department of Internal Medicine, Discipline of Cardiology, University of Campinas, Campinas, Brazil
| | - Marta Belmonte
- Cardiovascular Center Aalst, onze lieve vrouw Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy
| | - Hirofumi Ohashi
- Cardiovascular Center Aalst, onze lieve vrouw Clinic, Aalst, Belgium; Department of Cardiology, Aichi Medical University, Aichi, Japan
| | - Koshiro Sakai
- Cardiovascular Center Aalst, onze lieve vrouw Clinic, Aalst, Belgium; Division of Cardiology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
| | - Emanuele Gallinoro
- Cardiovascular Center Aalst, onze lieve vrouw Clinic, Aalst, Belgium; Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy
| | - Emanuele Barbato
- Cardiovascular Center Aalst, onze lieve vrouw Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy
| | - Thomas Engstrøm
- Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Javier Escaned
- Instituto de Investigacion Sanitaria Del Hospital Clinico San Carlos, Complutense University, Madrid, Spain
| | - Ziad A Ali
- St. Francis Hospital & Heart Center, Roslyn, NY, USA
| | - Morton J Kern
- University of California Irvine and Veterans Affairs Long Beach Healthcare System, Irvine, California, USA
| | - Nico H J Pijls
- Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands; Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Peter Jüni
- Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Bernard De Bruyne
- Cardiovascular Center Aalst, onze lieve vrouw Clinic, Aalst, Belgium; Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.
| |
Collapse
|
9
|
Waksman R, Pahuja M, van Diepen S, Proudfoot AG, Morrow D, Spitzer E, Nichol G, Weisfeldt ML, Moscucci M, Lawler PR, Mebazaa A, Fan E, Dickert NW, Samsky M, Kormos R, Piña IL, Zuckerman B, Farb A, Sapirstein JS, Simonton C, West NEJ, Damluji AA, Gilchrist IC, Zeymer U, Thiele H, Cutlip DE, Krucoff M, Abraham WT. Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium (SHARC). Circulation 2023; 148:1113-1126. [PMID: 37782695 PMCID: PMC11025346 DOI: 10.1161/circulationaha.123.064527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 07/31/2023] [Indexed: 10/04/2023]
Abstract
The Shock Academic Research Consortium is a multi-stakeholder group, including representatives from the US Food and Drug Administration and other government agencies, industry, and payers, convened to develop pragmatic consensus definitions useful for the evaluation of clinical trials enrolling patients with cardiogenic shock, including trials evaluating mechanical circulatory support devices. Several in-person and virtual meetings were convened between 2020 and 2022 to discuss the need for developing the standardized definitions required for evaluation of mechanical circulatory support devices in clinical trials for cardiogenic shock patients. The expert panel identified key concepts and topics by performing literature reviews, including previous clinical trials, while recognizing current challenges and the need to advance evidence-based practice and statistical analysis to support future clinical trials. For each category, a lead (primary) author was assigned to perform a literature search and draft a proposed definition, which was presented to the subgroup. These definitions were further modified after feedback from the expert panel meetings until a consensus was reached. This manuscript summarizes the expert panel recommendations focused on outcome definitions, including efficacy and safety.
Collapse
Affiliation(s)
- Ron Waksman
- Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC (R.W.)
| | - Mohit Pahuja
- Division of Cardiology, University of Oklahoma Health Sciences Center, Oklahoma City (M.P.)
| | - Sean van Diepen
- Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada (S.v.D.)
| | - Alastair G Proudfoot
- Department of Perioperative Medicine, Barts Heart Centre, London, UK (A.G.P.)
- Department of Cardiac Anesthesiology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Germany (A.G.P.)
| | - David Morrow
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (D.M.)
| | - Ernest Spitzer
- Cardialysis, Rotterdam, The Netherlands (E.S.)
- Cardiology Department, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (E.S.)
| | - Graham Nichol
- University of Washington-Harborview Center for Prehospital Emergency Care, University of Washington Harborview Center, Seattle (G.N.)
| | - Myron L Weisfeldt
- Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD (M.L.W.)
| | - Mauro Moscucci
- Office of Cardiovascular Devices, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD (M.M., B.Z., A.F., J.S.S.)
| | - Patrick R Lawler
- Peter Munk Cardiac Centre, Toronto General Hospital Research Institute, Canada (P.R.L.)
- McGill University Health Centre, Montreal, Canada (P.R.L.)
- Interdepartmental Division of Critical Care Medicine, University of Toronto, Canada (P.R.L.)
| | - Alexandre Mebazaa
- Université Paris Cité, Department of Anesthesiology and Critical Care Medicine, Hôpital Lariboisière, France (A.M.)
| | - Eddy Fan
- Interdepartmental Division of Critical Care Medicine, University of Toronto, Canada (E.F.)
| | - Neal W Dickert
- Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA (N.W.D.)
| | - Marc Samsky
- Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT (M.S.)
| | - Robert Kormos
- Global Medical Affairs Heart Failure, Abbott Laboratories, Austin, TX (R.K.)
| | - Ileana L Piña
- Division of Cardiology, Thomas Jefferson University, Philadelphia, PA (I.L.P.)
| | - Bram Zuckerman
- Office of Cardiovascular Devices, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD (M.M., B.Z., A.F., J.S.S.)
| | - Andrew Farb
- Office of Cardiovascular Devices, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD (M.M., B.Z., A.F., J.S.S.)
| | - John S Sapirstein
- Office of Cardiovascular Devices, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD (M.M., B.Z., A.F., J.S.S.)
| | | | | | - Abdulla A Damluji
- Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, VA (A.A.D.)
| | - Ian C Gilchrist
- Department of Interventional Cardiology/Heart and Vascular Institute, Penn State Health/Hershey Medical Center (I.C.G.)
| | - Uwe Zeymer
- Institut für Herzinfarktforschung Ludwigshafen, Germany (U.Z.)
| | - Holger Thiele
- Heart Center Leipzig at University of Leipzig, Germany (H.T.)
- Leipzig Heart Science, Germany (H.T.)
| | - Donald E Cutlip
- Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA (D.E.C.)
| | - Mitchell Krucoff
- Department of Medicine, Duke University School of Medicine, Durham, NC (M.K.)
| | - William T Abraham
- Division of Cardiovascular Medicine and the Davis Heart and Lung Research Institute, The Ohio State University College of Medicine/Ohio State University Wexner Medical Center, Columbus (W.T.A.)
| |
Collapse
|
10
|
Chandra P, Sethuraman S, Roy S, Mohanty A, Parikh K, Charantharalyil Gopalan B, Sahoo PK, Kasturi S, Shah VT, Kumar V, Pinto B, Rath PC, Yerramareddy VR, Davidson D, Navasundi GB, Subban V, Livingston N, Rajaraman DP, Narang M, West NEJ, Mullasari A. Effectiveness and safety of optical coherence tomography-guided PCI in Indian patients with complex lesions: A multicenter, prospective registry. Indian Heart J 2023; 75:236-242. [PMID: 37244397 PMCID: PMC10421993 DOI: 10.1016/j.ihj.2023.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Revised: 04/30/2023] [Accepted: 05/21/2023] [Indexed: 05/29/2023] Open
Abstract
BACKGROUND Optical coherence tomography (OCT) is reported to be a feasible and safe imaging modality for the guidance of percutaneous coronary intervention (PCI) of complex lesions. METHODS This multicenter, prospective registry assessed the minimum stent area (MSA) achieved under OCT guidance. A performance goal of 24% improvement in MSA over and above the recommendation set by the European Association of Percutaneous Cardiovascular Interventions Consensus 2018 (4.5 mm2 MSA for non-left main and 3.5 mm2 for small vessels). The incidence of contrast-induced nephropathy was also assessed. Core lab analysis was conducted. RESULTS Five hundred patients (average age: 59.4 ± 10.1 years; 83% males) with unstable angina (36.8%), NSTEMI (26.4%), and STEMI (22%) were enrolled. The primary endpoint was achieved in 93% of lesions with stent diameter ≥2.75 mm (average MSA: 6.44 mm2) and 87% of lesions with stent diameter ≤2.5 mm (average MSA: 4.56 mm2). The average MSA (with expansion ≥80% cutoff) was 6.63 mm2 and 4.74 mm2 with a stent diameter ≥2.75 mm and ≤2.5 mm, respectively. According to the core lab analysis, the average MSA achieved with a stent diameter ≥2.75 mm and ≤2.5 mm was 6.23 mm2 and 3.95 mm2, respectively (with expansion ≥80% cutoff). Clinically significant serum creatinine was noted in two patients (0.45%). Major adverse cardiac events at 1 year were noted in 1.2% (n = 6) of the patients; all were cardiac deaths. CONCLUSION PCI under OCT guidance improves procedural and long-term clinical outcomes in patients with complex lesions not just in a controlled trial environment but also in routine clinical practice.
Collapse
Affiliation(s)
- Praveen Chandra
- Interventional and Structural Heart Cardiology, Interventional Cardiology Heart Institute, Medanta-The Medicity, Gurgaon, Haryana, India.
| | - Selvamani Sethuraman
- Department of Cardiology, Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu, India
| | - Sanjeeb Roy
- Interventional Cardiology, Intervention Cardiology, Fortis Escorts Hospital, Jaipur, Rajasthan, India
| | - Arun Mohanty
- Department of Cardiology, Sir Ganga Ram Hospital, New Delhi, Delhi, India
| | - Keyur Parikh
- Intervention Cardiology, Marengo CIMS Hospital, Ahmedabad, Gujarat, India
| | | | - Prasant Kumar Sahoo
- Interventional Cardiology, Department of Cardiology, Apollo Hospital, Bhubaneshwar, Odisha, India
| | - Sridhar Kasturi
- Department of Cardiology, Sunshine Hospital, Hyderabad, Telangana, India
| | | | - Viveka Kumar
- Cardiac Sciences, Department of Cardiology, Max Super Specialty Hospital, Saket, New Delhi, Delhi, India
| | - Brian Pinto
- Department of Cardiology, Holy Family Hospital, Mumbai, Maharashtra, India
| | | | | | - Deepak Davidson
- Intervention Cardiology, Caritas Hospital, Kottayam, Kerala, India
| | - Girish B Navasundi
- Interventional Cardiology, Department of Cardiology, Apollo Hospital, Bangalore, Karnataka, India
| | - Vijayakumar Subban
- Indian Cardiology Research Foundation, Core Lab, Chennai, Tamil Nadu, India
| | | | | | | | | | - Ajit Mullasari
- Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India
| |
Collapse
|
11
|
Karimi Galougahi K, Dakroub A, Chau K, Mathew R, Mullasari A, Singh B, Sengottuvelu G, Maehara A, Mintz G, Jeremias A, Shlofmitz E, West NEJ, Shlofmitz R, Ali ZA. Utility of optical coherence tomography in acute coronary syndromes. Catheter Cardiovasc Interv 2023. [PMID: 37245076 DOI: 10.1002/ccd.30656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Accepted: 03/24/2023] [Indexed: 05/29/2023]
Abstract
Studies utilizing intravascular imaging have replicated the findings of histopathological studies, identifying the most common substrates for acute coronary syndromes (ACS) as plaque rupture, erosion, and calcified nodule, with spontaneous coronary artery dissection, coronary artery spasm, and coronary embolism constituting the less common etiologies. The purpose of this review is to summarize the data from clinical studies that have used high-resolution intravascular optical coherence tomography (OCT) to assess culprit plaque morphology in ACS. In addition, we discuss the utility of intravascular OCT for effective treatment of patients presenting with ACS, including the possibility of culprit lesion-based treatment by percutaneous coronary intervention.
Collapse
Affiliation(s)
| | | | - Karen Chau
- St Francis Hospital, Roslyn, New York, USA
| | | | - Ajit Mullasari
- Institute of Cardio-Vascular Diseases, Madras Medical Mission, Chennai, India
| | | | | | - Akiko Maehara
- St Francis Hospital, Roslyn, New York, USA
- Cardiovascular Research Foundation, New York, New York, USA
| | - Gary Mintz
- Cardiovascular Research Foundation, New York, New York, USA
| | | | | | | | - Richard Shlofmitz
- St Francis Hospital, Roslyn, New York, USA
- Cardiovascular Research Foundation, New York, New York, USA
| | - Ziad A Ali
- St Francis Hospital, Roslyn, New York, USA
- Cardiovascular Research Foundation, New York, New York, USA
| |
Collapse
|
12
|
Stone GW, Kereiakes DJ, Gori T, Metzger DC, Stein B, Erickson M, Torzewski J, Kabour A, Piegari G, Cavendish J, Bertolet B, Stockelman KA, West NEJ, Ben-Yehuda O, Choi JW, Marx SO, Spertus JA, Ellis SG. Five-Year Clinical Outcomes After Coronary Bioresorbable Scaffolds and Drug-Eluting Stents: The ABSORB IV Randomized Trial. J Am Coll Cardiol 2023:S0735-1097(23)05527-4. [PMID: 37207924 DOI: 10.1016/j.jacc.2023.05.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 05/02/2023] [Accepted: 05/04/2023] [Indexed: 05/21/2023]
Abstract
BACKGROUND Bioresorbable vascular scaffolds (BVS) were designed to improve late event-free survival compared with metallic drug-eluting stents. However, initial trials demonstrated worse early outcomes with BVS, in part due to suboptimal technique. In the large-scale, blinded ABSORB IV trial, polymeric everolimus-eluting BVS implanted with improved technique demonstrated non-inferior 1-year outcomes compared with cobalt chromium everolimus-eluting stents (CoCr-EES). OBJECTIVES To evaluate the long-term outcomes from the ABSORB IV trial. METHODS We randomized 2,604 patients at 147 sites with stable or acute coronary syndromes to BVS with improved technique vs. CoCr-EES. Patients, clinical assessors and event adjudicators were blinded to randomization. Five-year follow-up was completed. RESULTS Target lesion failure (TLF) at 5 years occurred in 216 patients (17.5%) assigned to BVS and 180 patients (14.5%) assigned to CoCr-EES (P=0.03). Device thrombosis within 5 years occurred in 21 (1.7%) BVS and 13 (1.1%) CoCr-EES patients (P=0.15). Event rates were slightly greater with BVS than CoCr-EES through 3-year follow-up and similar between 3-5 years. Angina, also centrally adjudicated, recurred within 5 years in 659 patients (cumulative rate 53.0%) assigned to BVS and 674 patients (53.3%) assigned to CoCr-EES (P=0.63). CONCLUSIONS In this large-scale, blinded randomized trial, despite improved implantation technique the absolute 5-year rate of TLF was 3% greater after BVS compared with CoCr-EES. The risk period for increased events was restricted to 3 years, the time point of complete scaffold bioresorption; event rates were similar thereafter. Angina recurrence after intervention was frequent during 5-year follow-up but was comparable with both devices.
Collapse
Affiliation(s)
- Gregg W Stone
- Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
| | - Dean J Kereiakes
- The Carl and Edyth Lindner Research Center at The Christ Hospital, Cincinnati, OH
| | - Tommaso Gori
- Kardiologie I University Medical Center and DZHK Rhein-Main, Mainz, Germany
| | | | - Bernardo Stein
- Ballad Health Systems CVA Heart Institute, Kingsport, TN
| | | | | | - Ameer Kabour
- Cardiovascular Center Oberallgäu-Kempten, Kempten, Germany
| | - Guy Piegari
- Mercy St. Vincent Medical Center, Toledo, OH
| | | | | | | | | | | | - James W Choi
- Texas Health Presbyterian Hospital and the Baylor Research Institute, Dallas, TX
| | - Steven O Marx
- NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY
| | - John A Spertus
- University of Missouri - Kansas City (UMKC) and Saint Luke's Mid America Heart Institute/University of Missouri - Kansas City (UMKC), Kansas City, MO
| | | |
Collapse
|
13
|
Gerhardt T, Stähli BE, Rudolph TK, Lutz M, Schatz AS, Zanders L, Schubert T, Stueve M, West NEJ, Boone E, Landmesser U, Leistner DM. Prognostic impact of fractional flow reserve measurements in patients with acute coronary syndromes: a subanalysis of the FLORIDA study. Heart Vessels 2023:10.1007/s00380-023-02256-7. [PMID: 37067577 DOI: 10.1007/s00380-023-02256-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Accepted: 03/01/2023] [Indexed: 04/18/2023]
Abstract
Randomized trials suggest benefits for fractional flow reserve (FFR)-guided vs. angiography-guided treatment strategies in well-defined and selected patient cohorts with acute coronary syndromes (ACS). The long-term prognostic value of FFR measurement in unselected all-comer ACS patients, however, remains unknown. This subanalysis of the Fractional FLOw Reserve In cardiovascular DiseAses (FLORIDA) study sought to investigate the long-term effects of FFR in the management of lesions in patients with acute coronary syndrome (ACS). FLORIDA was an observational all-comer cohort study performed in Germany, that was population-based and unselected. Patients enrolled into the anonymized InGef Research Database presenting with ACS and undergoing coronary angiography between January 2014 and December 2015 were included in the analysis. Patients were stratified into either the FFR-guided or the angiography-guided treatment arm, based on the treatment received. A matched cohort study design was used. The primary endpoint was all-cause mortality. The secondary endpoint was major adverse cardiovascular events (MACE), a composite of death, non-fatal myocardial infarction (MI), and repeat revascularization. Follow-up time was 3 years. Rates of 3-year mortality were 10.2 and 14.0% in the FFR-guided and the angiography-guided treatment arms (p = 0.04), corresponding to a 27% relative risk reduction for FFR in ACS patients. Rates of MACE were similar in both arms (47.7 vs. 51.5%, p = 0.14), including similar rates of non-fatal MI (27.7 vs. 25.4%, p = 0.47) and revascularization (9.9 vs. 12.1%, p = 0.17). In this large, all-comer observational study of ACS patients, FFR-guided revascularization was associated with a lower mortality at 3 years. This finding encourages the routine use of FFR to guide lesion revascularization in patients presenting with ACS.
Collapse
Affiliation(s)
- Teresa Gerhardt
- Klinik für Kardiologie, Charité Campus Benjamin Franklin, Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, 12203, Berlin, Germany
| | - Barbara E Stähli
- Klinik für Kardiologie, Universitäres Herzzentrum, Universitätsspital Zürich, Zurich, Switzerland
| | - Tanja K Rudolph
- Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen, Germany
| | - Matthias Lutz
- Universitätsklinik Schleswig-Holstein, Kiel, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site North, 24105, Kiel, Germany
| | - Anne-Sophie Schatz
- Klinik für Kardiologie, Charité Campus Benjamin Franklin, Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
| | - Lukas Zanders
- Klinik für Kardiologie, Charité Campus Benjamin Franklin, Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
- University Heart & Vascular Center Frankfurt, Frankfurt, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site Rhein/Main, Frankfurt, Germany
| | | | | | | | - Els Boone
- Abbott Vascular, Santa Clara, CA, USA
| | - Ulf Landmesser
- Klinik für Kardiologie, Charité Campus Benjamin Franklin, Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, 12203, Berlin, Germany
| | - David M Leistner
- Berlin Institute of Health (BIH), 10117, Berlin, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, 12203, Berlin, Germany.
- University Heart & Vascular Center Frankfurt, Frankfurt, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Rhein/Main, Frankfurt, Germany.
| |
Collapse
|
14
|
Low AF, Wongpraparut N, Chunhamaneewat N, Jeamanukoolkit A, Jhung LT, Zhen-Vin L, Tan CT, Hwa HH, Rajagopal R, Yahya AF, Kaur R, Narang M, West NEJ. Clinical use of optical coherence tomography during percutaneous coronary intervention and coronary procedures in Southeast Asia: a survey-based expert consensus summary. AsiaIntervention 2023; 9:25-31. [PMID: 36936105 PMCID: PMC10015489 DOI: 10.4244/aij-d-22-00059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/15/2022] [Accepted: 09/12/2022] [Indexed: 03/14/2023]
Abstract
Optical coherence tomography (OCT), an established intravascular imaging technique, enables rapid acquisition of high-resolution images during invasive coronary procedures to assist physician decision-making. OCT has utility in identifying plaque/lesion morphology (e.g., thrombus, degree of calcification, and presence of lipid) and vessel geometry (lesion length and vessel diameter) and in guiding stent optimisation through identification of malapposition and underexpansion. The use of OCT guidance during percutaneous coronary interventions (PCI) has demonstrated improved procedural and clinical outcomes in longitudinal registries, although randomised controlled trial data remain pending. Despite growing data and guideline endorsement to support OCT guidance during PCI, its use in different countries is not well established. This article is based on an advisory panel meeting that included experts from Southeast Asia (SEA) and is aimed at understanding the current clinical utility of intracoronary imaging and OCT, assessing the barriers and enablers of imaging and OCT adoption, and mapping a path for the future of intravascular imaging in SEA. This is the first Southeast Asian consensus that provides insights into the use of OCT from a clinician's point of view.
Collapse
Affiliation(s)
- Adrian F Low
- National University Heart Centre Singapore, National University Hospital, Singapore
| | - Nattawut Wongpraparut
- Cardiac Catheterisation Laboratory, Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | | | | | | | - Lee Zhen-Vin
- University Malaya Medical Centre, Kuala Lumpur, Malaysia
| | | | | | | | - Achmad Fauzi Yahya
- Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital- Bandung, Indonesia
| | | | | | | |
Collapse
|
15
|
Osborn EA, Johnson M, Maksoud A, Spoon D, Zidar FJ, Korngold EC, Buccola J, Garcia Cabrera H, Rapoza RJ, West NEJ, Rauch J. Safety and efficiency of percutaneous coronary intervention using a standardised optical coherence tomography workflow. EUROINTERVENTION 2023; 18:1178-1187. [PMID: 36373421 PMCID: PMC9936255 DOI: 10.4244/eij-d-22-00512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 09/05/2022] [Indexed: 02/19/2023]
Abstract
BACKGROUND While intravascular imaging guidance during percutaneous coronary intervention (PCI) improves outcomes, routine intravascular imaging usage remains low, in part due to perceived inefficiency and safety concerns. Aims: The LightLab (LL) Initiative was designed to evaluate whether implementing a standardised optical coherence tomography (OCT) workflow impacts PCI safety metrics and procedural efficiency. METHODS In this multicentre, prospective, observational study, PCI procedural data were collected over 2 years from 45 physicians at 17 US centres. OCT-guided PCI incorporating the LL workflow (N=264), a structured algorithm using routine pre- and post-PCI OCT imaging, was compared with baseline angiography-only PCI (angio) (N=428). Propensity score analysis identified 207 matched procedures. Outcomes included procedure time, radiation exposure, contrast volume, device utilisation, and treatment strategy. RESULTS Compared with angiography alone, LL workflow OCT-guided PCI increased the median procedural time by 9 minutes but reduced vessel preparation time (2 min LL workflow vs 3 min angio; p<0.001) and resulted in less unplanned additional treatment (4% LL workflow vs 10% angio; p=0.01). With LL workflow OCT guidance, fewer cineangiography views were needed compared to angiography guidance, leading to decreased radiation exposure (1,133 mGy LL workflow vs 1,269 mGy angio; p=0.02), with no difference in contrast utilisation between groups (p=0.28). Furthermore, LL workflow OCT guidance resulted in fewer predilatation balloons and stents being used, more direct stent placement, and greater stent post-dilatation than angiography-guided PCI. CONCLUSIONS The incorporation of a standardised pre- and post-PCI OCT imaging workflow improves procedural efficiency and safety metrics, at a cost of a modestly longer procedure time.
Collapse
Affiliation(s)
- Eric A Osborn
- Cardiology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Michael Johnson
- Montefiore Einstein Center for Heart and Vascular Care, Bronx, NY, USA
| | - Aziz Maksoud
- Cardiovascular Research Institute of Kansas, University of Kansas School of Medicine, Wichita, KS, USA
- Kansas Heart Hospital, Wichita, KS, USA
| | - Daniel Spoon
- International Heart Institute of Montana, Missoula, MT, USA
| | | | | | | | | | | | | | - Judah Rauch
- Montefiore Einstein Center for Heart and Vascular Care, Bronx, NY, USA
| |
Collapse
|
16
|
Lundy EF, Karimi Galougahi K, Dominguez-Sulca D, Chowdhury E, Thomas SV, Porter CR, Mintz GS, Matsumura M, Maehara A, Cohen DJ, Moses JW, Shlofmitz ES, Jeremias A, West NEJ, Robinson NB, Shlofmitz RA, Ali ZA. Visualizing Inside Conduits-Intraoperative Screening of Grafts by Optical Coherence Tomography. Ann Thorac Surg 2023; 115:266-271. [PMID: 35970228 DOI: 10.1016/j.athoracsur.2022.07.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 07/19/2022] [Accepted: 07/25/2022] [Indexed: 12/31/2022]
Abstract
PURPOSE Saphenous vein graft (SVG) failure is a complex phenomenon, with technical, biologic, and local factors contributing to early and medium- and long-term failure after coronary artery bypass graft. Both technical and conduit factors may have significant impact on early SVG failure. DESCRIPTION We review the complex factors that play a pathogenic role in SVG failure, followed by review of the existing literature on potential utility of high-definition optical coherence tomography (OCT) in comprehensive intraoperative assessment of SVGs. EVALUATION We describe a new technique for intraoperative acquisition of OCT images in the harvested SVGs and introduce a classification system for pathologic processes that can be detected in the harvested SVG conduits by OCT. CONCLUSIONS The potential impact on early graft failure of the exclusion of segments of SVGs that are less than optimal (ie, containing fibroatheroma, retained thrombus, sclerotic valves, or procurement injury) will be examined in the randomized controlled OCTOCAB (Intraoperative Optical Coherence Tomography of the Saphenous Vein Conduit in Patients Undergoing Coronary Artery Bypass Surgery) trial.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Gary S Mintz
- Cardiovascular Research Foundation, New York, New York
| | | | - Akiko Maehara
- Cardiovascular Research Foundation, New York, New York
| | - David J Cohen
- St Francis Hospital & Heart Center, Roslyn, New York; Cardiovascular Research Foundation, New York, New York
| | - Jeffrey W Moses
- St Francis Hospital & Heart Center, Roslyn, New York; Cardiovascular Research Foundation, New York, New York
| | | | - Allen Jeremias
- St Francis Hospital & Heart Center, Roslyn, New York; Cardiovascular Research Foundation, New York, New York
| | | | | | | | - Ziad A Ali
- St Francis Hospital & Heart Center, Roslyn, New York; Cardiovascular Research Foundation, New York, New York.
| |
Collapse
|
17
|
West NEJ, Boone E. The future of personalized care for vascular patients: an industry perspective. Eur Heart J Suppl 2022; 24:H57-H61. [DOI: 10.1093/eurheartjsupp/suac056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Healthcare has entered a brave new world in the early part of the 21st century: the landscape has changed and continues to change rapidly, evolving at a rate as never seen before. Fuelled by technological advancement, big data analytics, and the explosion of apps and sensors, as well as by telemedicine and remote monitoring needs driven by the COVID-19 pandemic, the healthcare ecosystem is metamorphosing literally before our eyes. So, what is the role for the Medtech industry as healthcare systems reshape themselves to address emerging patients’ needs and desires, and how can the use of data and novel technologies be leveraged to bring about the kind of change needed to deliver truly holistic patient care?
Collapse
Affiliation(s)
- Nick E J West
- Abbott Vascular, Santa Clara , 3200 Lakeside Drive, Santa Clara, CA 95054 , USA
| | - Els Boone
- Abbott Vascular, Santa Clara , 3200 Lakeside Drive, Santa Clara, CA 95054 , USA
| |
Collapse
|
18
|
Buccola J, Meinen J, Spinelli J, Hammerstone M, Rapoza R, West NEJ. Investigating real-world impact of optical coherence tomography workflow-guided coronary interventions: Design and rationale of the LightLab Clinical Initiative. Catheter Cardiovasc Interv 2022; 100 Suppl 1:S1-S6. [PMID: 36661368 DOI: 10.1002/ccd.30394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Accepted: 08/18/2022] [Indexed: 01/21/2023]
Abstract
OBJECTIVE The LightLab Clinical Initiative was designed to examine adoption of optical coherence tomography (OCT) imaging during routine percutaneous coronary intervention (PCI) practice, and enable identification and reduction of barriers to broader adoption of intracoronary imaging in real-world practice. BACKGROUND Intracoronary imaging guidance during PCI has been shown to improve clinical outcomes and features as a recommendation in societal guidelines, yet widespread routine adoption remains low. Perceived barriers to utilization include familiarity with, and ability to interpret imaging, concerns over added procedure time and contrast load, alongside a lack of actionable outcome data. METHODS AND RESULTS LightLab was a multicenter prospective observational data-gathering project, conducted between January 2019, and June 2021, with 17 participating hospitals and physicians. Data were gathered in real-time, where OCT guidance was employed during PCI using a standardized OCT-guided workflow algorithm, MLD MAX (where MLD stands for plaque Morphology, lesion Length, vessel Diameter and MAX for Medial dissection, stent Apposition, stent eXpansion) which was developed to simplify and integrate information from OCT throughout the PCI procedure. Integration of this workflow/algorithm was implemented through a series of phases, focusing on physician decision-making, efficiency, and safety improvements during the procedure. CONCLUSIONS Through real-time, prospective procedural data acquisition in the cardiac catheterization laboratory setting, the LightLab Clinical Initiative demonstrates the impact of a standardized OCT-guided workflow on procedural metrics, including time, contrast use, radiation exposure, as well as financial efficiencies such as device utilization. These results can potentially mitigate underlying concerns over the utility of adoption of intracoronary imaging guidance during PCI.
Collapse
|
19
|
Siddiqi TJ, Khan MS, Karimi Galougahi K, Shlofmitz E, Moses JW, Rao S, West NEJ, Wolff E, Hochler J, Chau K, Khalique O, Shlofmitz RA, Jeremias A, Ali ZA. Optical coherence tomography versus angiography and intravascular ultrasound to guide coronary stent implantation: A systematic review and meta-analysis. Catheter Cardiovasc Interv 2022; 100 Suppl 1:S44-S56. [PMID: 36251325 DOI: 10.1002/ccd.30416] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2022] [Accepted: 09/02/2022] [Indexed: 01/24/2023]
Abstract
BACKGROUND Optical coherence tomography (OCT) is an adjunct to angiography-guided coronary stent placement. However, in the absence of dedicated, appropriately powered randomized controlled trials, the impact of OCT on clinical outcomes is unclear. OBJECTIVE To conduct a systematic review and meta-analysis of all available studies comparing OCT-guided versus angiography-guided and intravascular ultrasound (IVUS)-guided coronary stent implantation. METHODS MEDLINE and Cochrane Central were queried from their inception through July 2022 for all studies that sought to compare OCT-guided percutaneous coronary intervention (PCI) to angiography-guided and IVUS-guided PCI. The primary endpoint was minimal stent area (MSA) compared between modalities. Clinical endpoints of interest were all-cause and cardiovascular mortality, major adverse cardiovascular events (MACE), myocardial infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), and stent thrombosis (ST). Risk ratios (RRs) and mean differences (MDs) with their corresponding 95% confidence intervals (CIs) were pooled using a random-effects model. RESULTS Thirteen studies (8 randomized control trials and 5 observational studies) enrolling 6312 participants were included. OCT was associated with a strong trend toward increased MSA compared to angiography (MD = 0.36, p = 0.06). OCT-guided PCI was also associated with a reduction in the incidence of all-cause mortality [RR = 0.59, 95% CI (0.35, 0.97), p = 0.04] and cardiovascular mortality [RR = 0.41, 95% CI (0.21, 0.80), p = 0.009] compared with angiography-guided PCI. Point estimates favored OCT relative to angiography in MACE [RR = 0.75, 95% CI (0.47, 1.20), p = 0.22] and MI [RR = 0.75, 95% CI (0.53, 1.07), p = 0.12]. No differences were detected in ST [RR = 0.71, 95% CI (0.21, 2.44), p = 0.58], TLR [RR = 0.71, 95% CI (0.17, 3.05), p = 0.65], or TVR rates [RR = 0.89, 95% CI (0.46, 1.73), p = 0.73]. Compared with IVUS guidance, OCT guidance was associated with a nonsignificant reduction in the MSA (MD = -0.16, p = 0.27). The rates of all-cause and cardiovascular mortality, MACE, MI, TLR, TVR, or ST were similar between OCT-guided and IVUS-guided PCI. CONCLUSIONS OCT-guided PCI was associated with reduced all-cause and cardiovascular mortality compared to angiography-guided PCI. These results should be considered hypothesis generating as the mechanisms for the improved outcomes were unclear as no differences were detected in the rates of TLR, TVR, or ST. OCT- and IVUS-guided PCI resulted in similar post-PCI outcomes.
Collapse
Affiliation(s)
- Tariq Jamal Siddiqi
- Department of Medicine, University of Mississippi Medical Center, Jackson, USA
| | - Muhammad Shahzeb Khan
- Department of Medicine, Division of Cardiology, Duke University Medical Center, Raleigh-Durham, North Carolina, USA
| | - Keyvan Karimi Galougahi
- St. Francis Hospital, Roslyn, New York, USA.,Department of Medicine, Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA
| | | | - Jeffrey W Moses
- St. Francis Hospital, Roslyn, New York, USA.,Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, New York, USA
| | - Sunil Rao
- Department of Medicine, Division of Cardiology, Duke University Medical Center, Raleigh-Durham, North Carolina, USA
| | | | - Eric Wolff
- St. Francis Hospital, Roslyn, New York, USA
| | | | - Karen Chau
- St. Francis Hospital, Roslyn, New York, USA
| | | | | | - Allen Jeremias
- St. Francis Hospital, Roslyn, New York, USA.,Department of Medicine, Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA
| | - Ziad A Ali
- St. Francis Hospital, Roslyn, New York, USA.,Department of Medicine, Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA
| |
Collapse
|
20
|
Shlofmitz E, Croce K, Bezerra H, Sheth T, Chehab B, West NEJ, Shlofmitz R, Ali ZA. The MLD MAX OCT algorithm: An imaging-based workflow for percutaneous coronary intervention. Catheter Cardiovasc Interv 2022; 100 Suppl 1:S7-S13. [PMID: 36661367 DOI: 10.1002/ccd.30395] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Accepted: 08/18/2022] [Indexed: 01/21/2023]
Abstract
Although extensive clinical data support the utility of intravascular imaging to guide and optimize outcomes following percutaneous coronary interventions (PCI), clinical adoption remains limited. One of the primary reasons for limited utilization may be a lack of standardization on how to best integrate the data provided by intravascular imaging practically. Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality with integrated software automation that allows for incorporation of OCT into the routine workflow of PCIs. We suggest use of an algorithm called MLD MAX to incorporate OCT for imaging-guided interventions: the baseline OCT imaging run is intended to facilitate procedural planning and strategizing, consisting of assessment for predominant lesion morphology (M), measurement for stent length (L) and determination of stent diameter (D); the post-PCI OCT imaging run is designated for assessment of need for further optimization of stent result, and consists of analysis for medial dissections (M), adequate stent apposition (A) and stent expansion (X). Incorporation of the MLD MAX algorithm into daily practice guides an efficient and easily-memorable workflow for optimized PCI procedures.
Collapse
Affiliation(s)
- Evan Shlofmitz
- Department of Cardiology, St. Francis Hospital-The Heart Center, Roslyn, New York, USA
| | - Kevin Croce
- Division of Cardiovascular Medicine, Brigham & Women's Hospital, Boston, Massachusetts, USA
| | - Hiram Bezerra
- Division of Cardiovascular Medicine, Tampa General Hospital, University of South Florida Health, Tampa, Florida, USA
| | - Tej Sheth
- Division of Cardiology, McMaster University, Hamilton, Ontario, Canada
| | - Bassem Chehab
- Division of Cardiovascular Medicine, Kansas Heart Hospital, Wichita, Kansas, USA
| | | | - Richard Shlofmitz
- Department of Cardiology, St. Francis Hospital-The Heart Center, Roslyn, New York, USA
| | - Ziad A Ali
- Department of Cardiology, St. Francis Hospital-The Heart Center, Roslyn, New York, USA.,Cardiovascular Research Foundation, Clinical Trial Center, New York City, New York, USA
| |
Collapse
|
21
|
West NEJ, Juneja M, Pinilla N, De Loose KR, Henry TD, Baumgard CS, Kraineva O. Personalized vascular healthcare: insights from a large international survey. Eur Heart J Suppl 2022; 24:H8-H17. [PMID: 36382003 PMCID: PMC9650465 DOI: 10.1093/eurheartjsupp/suac052] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2024]
Abstract
Fragmentation of healthcare systems through limited cross-speciality communication and intermittent, intervention-based care, without insight into follow-up and compliance, results in poor patient experiences and potentially contributes to suboptimal outcomes. Data-driven tools and novel technologies have the capability to address these shortcomings, but insights from all stakeholders in the care continuum remain lacking. A structured online questionnaire was given to respondents (n = 1432) in nine global geographies to investigate attitudes to the use of data and novel technologies in the management of vascular disease. Patients with coronary or peripheral artery disease (n = 961), physicians responsible for their care (n = 345), and administrators/healthcare leaders with responsibility for commissioning/procuring cardiovascular services (n = 126) were included. Narrative themes arising from the survey included patients' desire for more personalized healthcare, shared decision-making, and improved communication. Patients, administrators, and physicians perceived and experienced deficiencies in continuity of care, and all acknowledged the potential for data-driven techniques and novel technologies to address some of these shortcomings. Further, physicians and administrators saw the 'upstream' segment of the care journey-before diagnosis, at point of diagnosis, and when determining treatment-as key to enabling tangible improvements in patient experience and outcomes. Finally, despite acceptance that data sharing is critical to the success of such interventions, there remains persistent issues related to trust and transparency. The current fragmented care continuum could be improved and streamlined through the adoption of advanced data analytics and novel technologies, including diagnostic and monitoring techniques. Such an approach could enable the refocusing of healthcare from intermittent contacts and intervention-only focus to a more holistic patient view.
Collapse
Affiliation(s)
- Nick E J West
- Abbott Vascular, 3200 Lakeside Drive, Santa Clara, CA 95054, USA
| | - Maneesh Juneja
- MJ Analytics Ltd, Hemel Hempstead, Hertfordshire HP1 1FW, UK
| | - Natalia Pinilla
- Division of Cardiology/Population Health Research Institute, McMaster University, Hamilton, ON L8L 2X2, Canada
| | - Koen R De Loose
- AZ Sint Blasius, Sint-Blasius, Kroonveldlaan 50, 9200 Dendermonde, Belgium
| | - Timothy D Henry
- The Carl and Edyth Lindner Research Center at The Christ Hospital, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA
| | | | - Olga Kraineva
- Abbott Vascular, 3200 Lakeside Drive, Santa Clara, CA 95054, USA
| |
Collapse
|
22
|
Khuddus MA, Darki A, Padaliya BB, West NEJ, Rapoza RJ, Buccola J, Amis G, Chehab BM, Secemsky EA. Improving efficiency and operator proficiency during percutaneous coronary interventions utilizing a standardized optical coherence tomography workflow. Catheter Cardiovasc Interv 2022; 100 Suppl 1:S14-S24. [PMID: 36661365 DOI: 10.1002/ccd.30392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2022] [Accepted: 08/18/2022] [Indexed: 01/21/2023]
Abstract
OBJECTIVES This study was designed to compare efficiency and quality metrics between percutaneous coronary intervention (PCI) procedures using optical coherence tomography (OCT) guided by a variable workflow versus a standardized workflow in a real-world population. BACKGROUND The LightLab (LL) Initiative was designed to evaluate the impact of a standardized OCT workflow during PCI to address barriers to adoption. METHODS The LL Initiative was a multicenter, prospective, observational study. PCI efficiency data were collected from 1/21/19 to 1/8/21 from 45 physicians at 17 US centers. OCT-guided PCIs were compared between baseline phase (variable workflow; N = 383) and the LL workflow utilization phase (N = 447). The LL workflow uses OCT to assess lesion Morphology, Length and Diameter, and then optimize outcomes by correcting for Medial dissection, stent mal-Apposition, and under-eXpansion (MLD MAX). Matching based on propensity scores was used to control for differences between PCIs. RESULTS After propensity matching, 291 paired procedures were included. Integration of the LL versus variable workflow resulted in no difference in procedure time (51 min vs. 51 min, p = 0.93). There was a reduction in radiation exposure (1124 mGy vs. 1493 mGy, p < 0.0001) and contrast volume (160 cc vs. 172 cc, p < 0.001). The LL workflow decreased the proportion of underexpanded lesions (34% vs. 54%, p < 0.0001) and improved minimum stent expansion (85% vs. 79%, p < 0.0001). Number of noncompliant balloons used was reduced with the LL workflow. (2.0 vs. 1.7, p < 0.01). CONCLUSIONS These data suggest that standardizing imaging with the LL workflow may overcome barriers to imaging and improve PCI outcomes without prolonging procedures.
Collapse
Affiliation(s)
- Matheen A Khuddus
- The Cardiac and Vascular Institute, Gainesville, Florida, USA.,HCA Florida North Florida Hospital, Gainesville, Florida, USA
| | - Amir Darki
- Loyola University Medical Center and Loyola Stritch School of Medicine, Maywood, Illinois, USA
| | - Bimal B Padaliya
- HonorHealth and the Scottsdale-Lincoln Health Network, Scottsdale, Arizona, USA
| | | | | | | | | | - Bassem M Chehab
- Ascension Via Christi Hospital, Cardiovascular Research Institute of Kansas, Wichita, Kansas, USA
| | - Eric A Secemsky
- Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | | |
Collapse
|
23
|
Damluji AA, Tehrani B, Sinha SS, Samsky MD, Henry TD, Thiele H, West NEJ, Senatore FF, Truesdell AG, Dangas GD, Smilowitz NR, Amin AP, deVore AD, Moazami N, Cigarroa JE, Rao SV, Krucoff MW, Morrow DA, Gilchrist IC. Position Statement on Vascular Access Safety for Percutaneous Devices in AMI Complicated by Cardiogenic Shock. JACC Cardiovasc Interv 2022; 15:2003-2019. [PMID: 36265932 PMCID: PMC10312149 DOI: 10.1016/j.jcin.2022.08.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Revised: 08/18/2022] [Accepted: 08/23/2022] [Indexed: 01/09/2023]
Abstract
In the United States, the frequency of using percutaneous mechanical circulatory support devices for acute myocardial infarction complicated by cardiogenic shock is increasing. These devices require large-bore vascular access to provide left, right, or biventricular cardiac support, frequently under urgent/emergent circumstances. Significant technical and logistical variability exists in device insertion, care, and removal in the cardiac catheterization laboratory and in the cardiac intensive care unit. This variability in practice may contribute to adverse outcomes observed in centers that receive patients with cardiogenic shock, who are at higher risk for circulatory insufficiency, venous stasis, bleeding, and arterial hypoperfusion. In this position statement, we aim to: 1) describe the public health impact of bleeding and vascular complications in cardiogenic shock; 2) highlight knowledge gaps for vascular safety and provide a roadmap for a regulatory perspective necessary for advancing the field; 3) propose a minimum core set of process elements, or "vascular safety bundle"; and 4) develop a possible study design for a pragmatic trial platform to evaluate which structured approach to vascular access drives most benefit and prevents vascular and bleeding complications in practice.
Collapse
Affiliation(s)
- Abdulla A Damluji
- Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, Virginia, USA; Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
| | - Behnam Tehrani
- Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, Virginia, USA
| | - Shashank S Sinha
- Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, Virginia, USA
| | - Marc D Samsky
- New York University School of Medicine, New York, New York, USA
| | - Timothy D Henry
- Carl and Edyth Lindner Center for Research and Education, Christ Hospital, Cincinnati, Ohio, USA
| | - Holger Thiele
- Heart Center Leipzig and Leipzig Heart Institute, Leipzig, Germany
| | | | - Fortunato F Senatore
- Division of Cardiology and Nephrology, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
| | - Alexander G Truesdell
- Inova Center of Outcomes Research, Inova Heart and Vascular Institute, Falls Church, Virginia, USA
| | - George D Dangas
- Division of Cardiology, Department of Medicine, Mount Sinai Hospital, New York, New York, USA
| | | | - Amit P Amin
- Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
| | - Adam D deVore
- Duke Clinical Research Institute, Durham, North Carolina, USA
| | - Nader Moazami
- New York University School of Medicine, New York, New York, USA
| | | | - Sunil V Rao
- New York University School of Medicine, New York, New York, USA
| | | | - David A Morrow
- Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Ian C Gilchrist
- Penn State Heart and Vascular Institute, Hershey Medical Center, Hershey, Pennsylvania, USA
| |
Collapse
|
24
|
Araki M, Park SJ, Dauerman HL, Uemura S, Kim JS, Di Mario C, Johnson TW, Guagliumi G, Kastrati A, Joner M, Holm NR, Alfonso F, Wijns W, Adriaenssens T, Nef H, Rioufol G, Amabile N, Souteyrand G, Meneveau N, Gerbaud E, Opolski MP, Gonzalo N, Tearney GJ, Bouma B, Aguirre AD, Mintz GS, Stone GW, Bourantas CV, Räber L, Gili S, Mizuno K, Kimura S, Shinke T, Hong MK, Jang Y, Cho JM, Yan BP, Porto I, Niccoli G, Montone RA, Thondapu V, Papafaklis MI, Michalis LK, Reynolds H, Saw J, Libby P, Weisz G, Iannaccone M, Gori T, Toutouzas K, Yonetsu T, Minami Y, Takano M, Raffel OC, Kurihara O, Soeda T, Sugiyama T, Kim HO, Lee T, Higuma T, Nakajima A, Yamamoto E, Bryniarski KL, Di Vito L, Vergallo R, Fracassi F, Russo M, Seegers LM, McNulty I, Park S, Feldman M, Escaned J, Prati F, Arbustini E, Pinto FJ, Waksman R, Garcia-Garcia HM, Maehara A, Ali Z, Finn AV, Virmani R, Kini AS, Daemen J, Kume T, Hibi K, Tanaka A, Akasaka T, Kubo T, Yasuda S, Croce K, Granada JF, Lerman A, Prasad A, Regar E, Saito Y, Sankardas MA, Subban V, Weissman NJ, Chen Y, Yu B, Nicholls SJ, Barlis P, West NEJ, Arbab-Zadeh A, Ye JC, Dijkstra J, Lee H, Narula J, Crea F, Nakamura S, Kakuta T, Fujimoto J, Fuster V, Jang IK. Optical coherence tomography in coronary atherosclerosis assessment and intervention. Nat Rev Cardiol 2022; 19:684-703. [PMID: 35449407 PMCID: PMC9982688 DOI: 10.1038/s41569-022-00687-9] [Citation(s) in RCA: 93] [Impact Index Per Article: 46.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/03/2022] [Indexed: 02/07/2023]
Abstract
Since optical coherence tomography (OCT) was first performed in humans two decades ago, this imaging modality has been widely adopted in research on coronary atherosclerosis and adopted clinically for the optimization of percutaneous coronary intervention. In the past 10 years, substantial advances have been made in the understanding of in vivo vascular biology using OCT. Identification by OCT of culprit plaque pathology could potentially lead to a major shift in the management of patients with acute coronary syndromes. Detection by OCT of healed coronary plaque has been important in our understanding of the mechanisms involved in plaque destabilization and healing with the rapid progression of atherosclerosis. Accurate detection by OCT of sequelae from percutaneous coronary interventions that might be missed by angiography could improve clinical outcomes. In addition, OCT has become an essential diagnostic modality for myocardial infarction with non-obstructive coronary arteries. Insight into neoatherosclerosis from OCT could improve our understanding of the mechanisms of very late stent thrombosis. The appropriate use of OCT depends on accurate interpretation and understanding of the clinical significance of OCT findings. In this Review, we summarize the state of the art in cardiac OCT and facilitate the uniform use of this modality in coronary atherosclerosis. Contributions have been made by clinicians and investigators worldwide with extensive experience in OCT, with the aim that this document will serve as a standard reference for future research and clinical application.
Collapse
Affiliation(s)
| | | | | | | | - Jung-Sun Kim
- Yonsei University College of Medicine, Seoul, South Korea
| | | | - Thomas W Johnson
- University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
| | | | - Adnan Kastrati
- Technische Universität München and Munich Heart Alliance, Munich, Germany
| | | | | | | | - William Wijns
- National University of Ireland Galway and Saolta University Healthcare Group, Galway, Ireland
| | | | | | - Gilles Rioufol
- Hospices Civils de Lyon and Claude Bernard University, Lyon, France
| | | | | | | | | | | | - Nieves Gonzalo
- Hospital Clinico San Carlos, IdISSC, Universidad Complutense, Madrid, Spain
| | | | - Brett Bouma
- Massachusetts General Hospital, Boston, MA, USA
| | | | - Gary S Mintz
- Cardiovascular Research Foundation, New York, NY, USA
| | - Gregg W Stone
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Christos V Bourantas
- Barts Health NHS Trust, University College London and Queen Mary University London, London, UK
| | - Lorenz Räber
- Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | | | | | | | | | - Myeong-Ki Hong
- Yonsei University College of Medicine, Seoul, South Korea
| | - Yangsoo Jang
- Yonsei University College of Medicine, Seoul, South Korea
| | | | - Bryan P Yan
- Chinese University of Hong Kong, Hong Kong, Hong Kong
| | - Italo Porto
- University of Genoa, Genoa, Italy, San Martino Hospital, IRCCS for Oncology and Neurosciences, Genoa, Italy
| | | | - Rocco A Montone
- Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | | | | | | | - Harmony Reynolds
- New York University Grossman School of Medicine, New York, NY, USA
| | - Jacqueline Saw
- Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
| | - Peter Libby
- Brigham and Women's Hospital, Boston, MA, USA
| | - Giora Weisz
- New York Presbyterian Hospital, Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY, USA
| | | | - Tommaso Gori
- Universitäts medizin Mainz and DZHK Rhein-Main, Mainz, Germany
| | | | | | | | | | | | - Osamu Kurihara
- Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan
| | | | | | | | - Tetsumin Lee
- Japanese Red Cross Musashino Hospital, Tokyo, Japan
| | - Takumi Higuma
- Kawasaki Municipal Tama Hospital, St. Marianna University School of Medicine, Kanagawa, Japan
| | | | - Erika Yamamoto
- Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Krzysztof L Bryniarski
- Jagiellonian University Medical College, Institute of Cardiology, Department of Interventional Cardiology, John Paul II Hospital, Krakow, Poland
| | | | | | | | - Michele Russo
- Catholic University of the Sacred Heart, Rome, Italy
| | | | | | - Sangjoon Park
- Korea Advanced Institute of Science and Technology, Daejeon, South Korea
| | - Marc Feldman
- University of Texas Health, San Antonio, TX, USA
| | | | - Francesco Prati
- UniCamillus - Saint Camillus International University of Health Sciences, Rome, Italy
| | - Eloisa Arbustini
- IRCCS Foundation University Hospital Policlinico San Matteo, Pavia, Italy
| | - Fausto J Pinto
- Santa Maria University Hospital, CHULN Center of Cardiology of the University of Lisbon, Lisbon School of Medicine, Lisbon Academic Medical Center, Lisbon, Portugal
| | - Ron Waksman
- MedStar Washington Hospital Center, Washington, DC, USA
| | | | - Akiko Maehara
- Cardiovascular Research Foundation, New York, NY, USA
| | - Ziad Ali
- Cardiovascular Research Foundation, New York, NY, USA
| | | | | | | | - Joost Daemen
- Erasmus University Medical Centre, Rotterdam, Netherlands
| | | | - Kiyoshi Hibi
- Yokohama City University Medical Center, Kanagawa, Japan
| | | | | | | | - Satoshi Yasuda
- Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Kevin Croce
- Brigham and Women's Hospital, Boston, MA, USA
| | | | | | | | | | | | | | | | | | - Yundai Chen
- Sixth Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Bo Yu
- The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | | | - Peter Barlis
- University of Melbourne, Melbourne, Victoria, Australia
| | | | | | - Jong Chul Ye
- Korea Advanced Institute of Science and Technology, Daejeon, South Korea
| | | | - Hang Lee
- Massachusetts General Hospital, Boston, MA, USA
| | - Jagat Narula
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Filippo Crea
- Catholic University of the Sacred Heart, Rome, Italy
| | | | | | - James Fujimoto
- Massachusetts Institute of Technology, Cambridge, MA, USA
| | | | - Ik-Kyung Jang
- Massachusetts General Hospital, Boston, MA, USA.
- Kyung Hee University, Seoul, South Korea.
| |
Collapse
|
25
|
Aetesam‐ur‐Rahman M, Zhao TX, Paques K, Oliveira J, Khialani B, Kyranis S, Braganza DM, Clarke SC, Bennett MR, West NEJ, Hoole SP. Coronary Flow Variations Following Percutaneous Coronary Intervention Affect Diastolic Nonhyperemic Pressure Ratios More Than the Whole Cycle Ratios. J Am Heart Assoc 2022; 11:e023554. [PMID: 35470686 PMCID: PMC9238611 DOI: 10.1161/jaha.121.023554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Background Post-percutaneous coronary intervention (PCI) fractional flow reserve ≥0.90 is an accepted marker of procedural success, and a cutoff of ≥0.95 has recently been proposed for post-PCI instantaneous wave-free ratio. However, stability of nonhyperemic pressure ratios (NHPRs) post-PCI is not well characterized, and transient reactive submaximal hyperemia post-PCI may affect their precision. We performed this study to assess stability and reproducibility of NHPRs post-PCI. Methods and Results Fifty-seven patients (age, 63.77±10.67 years; men, 71%) underwent hemodynamic assessment immediately post-PCI and then after a recovery period of 10, 20, and 30 minutes and repeated at 3 months. Manual offline analysis was performed to derive resting and hyperemic pressure indexes (Pd/Pa resting pressure gradient, mathematically derived instantaneous wave-free ratio, resting full cycle ratio, and fractional flow reserve) and microcirculatory resistances (basal microvascular resistance and index of microvascular resistance). Transient submaximal hyperemia occurring post-PCI was demonstrated by longer thermodilution time at 30 minutes compared with immediately post-PCI; mean difference of thermodilution time was 0.17 seconds (95% CI, 0.07-0.26 seconds; P=0.04). Basal microcirculatory resistance was also higher at 30 minutes than immediately post-PCI; mean difference of basal microvascular resistance was 10.89 mm Hg.s (95% CI, 2.25-19.52 mm Hg.s; P=0.04). Despite this, group analysis confirmed no significant differences in the values of resting whole cycle pressure ratios (Pd/Pa and resting full cycle ratio) as well as diastolic pressure ratios (diastolic pressure ratio and mathematically derived instantaneous wave-free ratio). Whole cardiac cycle NHPRs demonstrated the best overall stability post-PCI, and 1 in 5 repeated diastolic NHPRs crossed the clinical decision threshold. Conclusions Whole cycle NHPRs demonstrate better reproducibility and clinical precision post-PCI than diastolic NHPRs, possibly because of less perturbation from predominantly diastolic reactive hyperemia and left ventricular stunning. Registration URL: https://clinicaltrials.gov/ct2/show/NCT03502083; Unique identifier: NCT03502083 and URL: https://clinicaltrials.gov/ct2/show/NCT03076476; Unique identifier: NCT03076476.
Collapse
Affiliation(s)
| | - Tian X. Zhao
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| | - Kitty Paques
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| | - Joana Oliveira
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| | - Bharat Khialani
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| | - Stephen Kyranis
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| | - Denise M. Braganza
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| | - Sarah C. Clarke
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| | - Martin R. Bennett
- Division of Cardiovascular MedicineUniversity of CambridgeUnited Kingdom
| | - Nick E. J. West
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| | - Stephen P. Hoole
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| |
Collapse
|
26
|
Naidu SS, Baron SJ, Eng MH, Sathanandam SK, Zidar DA, Feldman DN, Ing FF, Latif F, Lim MJ, Henry TD, Rao SV, Dangas GD, Hermiller JB, Daggubati R, Shah B, Ang L, Aronow HD, Banerjee S, Box LC, Caputo RP, Cohen MG, Coylewright M, Duffy PL, Goldsweig AM, Hagler DJ, Hawkins BM, Hijazi ZM, Jayasuriya S, Justino H, Klein AJ, Kliger C, Li J, Mahmud E, Messenger JC, Morray BH, Parikh SA, Reilly J, Secemsky E, Shishehbor MH, Szerlip M, Yakubov SJ, Grines CL, Alvarez-Breckenridge J, Baird C, Baker D, Berry C, Bhattacharya M, Bilazarian S, Bowen R, Brounstein K, Cameron C, Cavalcante R, Culbertson C, Diaz P, Emanuele S, Evans E, Fletcher R, Fortune T, Gaiha P, Govender D, Gutfinger D, Haggstrom K, Herzog A, Hite D, Kalich B, Kirkland A, Kohler T, Laurisden H, Livolsi K, Lombardi L, Lowe S, Marhenke K, Meikle J, Moat N, Mueller M, Patarca R, Popma J, Rangwala N, Simonton C, Stokes J, Taber M, Tieche C, Venditto J, West NEJ, Zinn L. Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank. Catheter Cardiovasc Interv 2021; 98:904-913. [PMID: 34398509 DOI: 10.1002/ccd.29898] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Accepted: 07/28/2021] [Indexed: 01/07/2023]
Abstract
The Society for Cardiovascular Angiography and Interventions (SCAI) Think Tank is a collaborative venture that brings together interventional cardiologists, administrative partners, and select members of the cardiovascular industry community annually for high-level field-wide discussions. The 2021 Think Tank was organized into four parallel sessions reflective of the field of interventional cardiology: (a) coronary intervention, (b) endovascular medicine, (c) structural heart disease, and (d) congenital heart disease. Each session was moderated by a senior content expert and co-moderated by a member of SCAI's Emerging Leader Mentorship program. This document presents the proceedings to the wider cardiovascular community in order to enhance participation in this discussion, create additional dialog from a broader base, and thereby aid SCAI, the industry community and external stakeholders in developing specific action items to move these areas forward.
Collapse
Affiliation(s)
- Srihari S Naidu
- Department of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York, USA
| | - Suzanne J Baron
- Division of Cardiology, Department of Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA
| | - Marvin H Eng
- Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan, USA
| | - Shyam K Sathanandam
- Department of Cardiology, Le Bonheur Children's Hospital, Memphis, Tennessee, USA
| | - David A Zidar
- Department of Cardiology, UH Harrington Heart & Vascular Institute, Cleveland, Ohio, USA
| | - Dmitriy N Feldman
- Department of Cardiology, Weill Cornell Medical Center, New York, USA
| | - Frank F Ing
- Department of Cardiology, UC Davis Medical Center, Sacramento, California, USA
| | - Faisal Latif
- Department of Cardiology, The University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA
| | - Michael J Lim
- Department of Cardiology, St. Louis University School of Medicine, Saint Louis, Missouri, USA
| | - Timothy D Henry
- Department of Cardiology, The Christ Hospital Health Network, Cincinnati, Ohio, USA
| | - Sunil V Rao
- Department of Cardiology, Duke University Health System, Durham, North Carolina, USA
| | - George D Dangas
- The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, USA
| | - James B Hermiller
- Department of Cardiology, Ascension St. Vincent Cardiovascular Research Institute, Carmel, Indiana, USA
| | - Ramesh Daggubati
- Department of Cardiology, The West Virginia University School of Medicine, Morgantown, West Virginia, USA
| | - Binita Shah
- Department of Cardiology, NYU Grossman School of Medicine, New York, USA
| | - Lawrence Ang
- Division of Cardiovascular Medicine, The University of California, San Diego, California, USA
| | - Herbert D Aronow
- Department of Cardiology, Lifespan Cardiovascular Institute/Brown Medical School, Providence, Rhode Island, USA
| | - Subhash Banerjee
- Department of Cardiology, Dallas Veterans Affairs Medical Center, Dallas, Texas, USA
| | - Lyndon C Box
- Department of Cardiology, West Valley Medical Center, Caldwell, Idaho, USA
| | - Ronald P Caputo
- Department of Cardiology, Levine Heart and Wellness, Naples, Florida, USA
| | - Mauricio G Cohen
- Cardiac Catheterization Laboratory, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - Megan Coylewright
- Department of Cardiology, Erlanger Health System, Chattanooga, Tennessee, USA
| | - Peter L Duffy
- Department of Cardiology, West Florida Hospital, Pensacola, Florida, USA
| | - Andrew M Goldsweig
- Division of Cardiovascular Medicine, The University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Donald J Hagler
- Division of Pediatric Cardiology and Department of Cardiovascular Diseases, Mayo Clinic Health System, Rochester, Minnesota, USA
| | - Beau M Hawkins
- Department of Cardiology, The University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA
| | - Ziyad M Hijazi
- Cardiology, Weill Cornell Medical College, New York, USA.,Sidra Medicine, Doha, Qatar
| | - Sasanka Jayasuriya
- Cardiology, Ascension Columbia St. Mary's Hospital Milwaukee, Milwaukee, Wisconsin, USA
| | - Henri Justino
- Division of Cardiology, Department of Pediatrics, Texas Children's Hospital, Houston, Texas, USA
| | - Andrew J Klein
- Department of Cardiology, Piedmont Heart Institute, Atlanta, Georgia, USA
| | - Chad Kliger
- Department of Medicine, Division of Cardiovascular Medicine, Northwell Health Lenox Hill Hospital, New York, USA
| | - Jun Li
- Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA
| | - Ehtisham Mahmud
- Coronary Care Unit, University of California, San Diego, California, USA
| | - John C Messenger
- Department of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Brian H Morray
- Department of Cardiology, Seattle Children's Hospital, Seattle, Washington, USA
| | - Sahil A Parikh
- Division of Cardiology and Center for Interventional Vascular Therapy, Columbia University Irving Medical Center, New York, USA
| | - John Reilly
- Division of Cardiovascular Medicine, Department of Medicine, Stony Brook University Hospital, Stony Brook, New York, USA
| | - Eric Secemsky
- Department of Internal Medicine, Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Mehdi H Shishehbor
- Harrington Heart & Vascular Institute, UH Harrington Heart & Vascular Institute, Cleveland, Ohio, USA
| | - Molly Szerlip
- Division of Cardiology, Baylor Scott & White The Heart Hospital - Plano, Plano, Texas, USA
| | - Steven J Yakubov
- Department of Cardiology, OhioHealth Heart & Vascular Physicians, Columbus, Ohio, USA
| | - Cindy L Grines
- Department of Cardiology, Northside Hospital Cardiovascular Institute, Atlanta, Georgia, USA
| | -
- TandemLife, LivaNova, Pittsburgh, Pennsylvania, USA
| | | | | | - David Baker
- Philips Healthcare, Cambridge, Massachusetts, USA
| | | | | | | | | | | | | | | | | | | | | | - Erin Evans
- TandemLife, LivaNova, Pittsburgh, Pennsylvania, USA
| | | | | | - Priya Gaiha
- Siemens Medical Solutions USA, Malvern, Pennsylvania, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Neil Moat
- Abbott, Santa Clara, California, USA
| | | | | | | | | | | | - Jerry Stokes
- TandemLife, LivaNova, Pittsburgh, Pennsylvania, USA
| | | | | | | | | | | |
Collapse
|
27
|
Aetesam‐ur‐Rahman M, Brown AJ, Jaworski C, Giblett JP, Zhao TX, Braganza DM, Clarke SC, Agrawal BSK, Bennett MR, West NEJ, Hoole SP. Adenosine-Induced Coronary Steal Is Observed in Patients Presenting With ST-Segment-Elevation Myocardial Infarction. J Am Heart Assoc 2021; 10:e019899. [PMID: 34187187 PMCID: PMC8403291 DOI: 10.1161/jaha.120.019899] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Accepted: 01/21/2021] [Indexed: 12/22/2022]
Abstract
Background Adenosine is used to treat no-reflow in the infarct-related artery (IRA) during ST-segment-elevation myocardial infarction intervention. However, the physiological effect of adenosine in the IRA is variable. Coronary steal-a reduction of blood flow to the distal coronary bed-can occur in response to adenosine and this is facilitated by collaterals. We investigated the effects of adenosine on coronary flow reserve (CFR) in patients presenting with ST-segment-elevation myocardial infarction to better understand the physiological mechanism underpinning the variable response to adenosine. Methods and Results Pressure-wire assessment of the IRA after percutaneous coronary intervention was performed in 93 patients presenting with ST-segment-elevation myocardial infarction to calculate index of microvascular resistance, CFR, and collateral flow index by pressure. Modified collateral Rentrop grade to the IRA was recorded, as was microvascular obstruction by cardiac magnetic resonance imaging. Coronary steal (CFR <0.9), no change in flow (CFR=0.9-1.1), and hyperemic flow (CFR >1.1) after adenosine occurred in 19 (20%), 15 (16%), and 59 (63%) patients, respectively. Patients with coronary steal had higher modified Rentrop score to the IRA (1 [0, 1.75] versus 0 [0, 1], P<0.001) and a higher collateral flow index by pressure (0.25±0.10 versus 0.15±0.10, P=0.004) than the hyperemic group. The coronary steal group also had significantly higher index of microvascular resistance (61.68 [28.13, 87.04] versus 23.93 [14.67, 37.00], P=0.006) and had more disease (stenosis >50%) in the donor arteries (52.63% versus 22.03%, P=0.02) than the hyperemic group. Conclusions Adenosine-induced coronary steal may be responsible for a reduction in coronary flow reserve in a proportion of patients presenting with ST-segment-elevation myocardial infarction. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03145194. URL: https://www.isrctn.com; Unique identifier: ISRCTN3176727.
Collapse
Affiliation(s)
- Muhammad Aetesam‐ur‐Rahman
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
- Division of Cardiovascular MedicineUniversity of CambridgeCambridgeUnited Kingdom
| | - Adam J. Brown
- Department of CardiologyMonash UniversityMelbourneAustralia
| | | | - Joel P. Giblett
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
- Division of Cardiovascular MedicineUniversity of CambridgeCambridgeUnited Kingdom
| | - Tian X. Zhao
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
- Division of Cardiovascular MedicineUniversity of CambridgeCambridgeUnited Kingdom
| | - Denise M. Braganza
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| | - Sarah C. Clarke
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| | | | - Martin R. Bennett
- Division of Cardiovascular MedicineUniversity of CambridgeCambridgeUnited Kingdom
| | - Nick E. J. West
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| | - Stephen P. Hoole
- Department of Interventional CardiologyRoyal Papworth HospitalCambridgeUnited Kingdom
| |
Collapse
|
28
|
Tomaniak M, Katagiri Y, Modolo R, de Silva R, Khamis RY, Bourantas CV, Torii R, Wentzel JJ, Gijsen FJH, van Soest G, Stone PH, West NEJ, Maehara A, Lerman A, van der Steen AFW, Lüscher TF, Virmani R, Koenig W, Stone GW, Muller JE, Wijns W, Serruys PW, Onuma Y. Vulnerable plaques and patients: state-of-the-art. Eur Heart J 2021; 41:2997-3004. [PMID: 32402086 DOI: 10.1093/eurheartj/ehaa227] [Citation(s) in RCA: 82] [Impact Index Per Article: 27.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Revised: 11/01/2019] [Accepted: 03/26/2020] [Indexed: 01/21/2023] Open
Abstract
Despite advanced understanding of the biology of atherosclerosis, coronary heart disease remains the leading cause of death worldwide. Progress has been challenging as half of the individuals who suffer sudden cardiac death do not experience premonitory symptoms. Furthermore, it is well-recognized that also a plaque that does not cause a haemodynamically significant stenosis can trigger a sudden cardiac event, yet the majority of ruptured or eroded plaques remain clinically silent. In the past 30 years since the term 'vulnerable plaque' was introduced, there have been major advances in the understanding of plaque pathogenesis and pathophysiology, shifting from pursuing features of 'vulnerability' of a specific lesion to the more comprehensive goal of identifying patient 'cardiovascular vulnerability'. It has been also recognized that aside a thin-capped, lipid-rich plaque associated with plaque rupture, acute coronary syndromes (ACS) are also caused by plaque erosion underlying between 25% and 60% of ACS nowadays, by calcified nodule or by functional coronary alterations. While there have been advances in preventive strategies and in pharmacotherapy, with improved agents to reduce cholesterol, thrombosis, and inflammation, events continue to occur in patients receiving optimal medical treatment. Although at present the positive predictive value of imaging precursors of the culprit plaques remains too low for clinical relevance, improving coronary plaque imaging may be instrumental in guiding pharmacotherapy intensity and could facilitate optimal allocation of novel, more aggressive, and costly treatment strategies. Recent technical and diagnostic advances justify continuation of interdisciplinary research efforts to improve cardiovascular prognosis by both systemic and 'local' diagnostics and therapies. The present state-of-the-art document aims to present and critically appraise the latest evidence, developments, and future perspectives in detection, prevention, and treatment of 'high-risk' plaques occurring in 'vulnerable' patients.
Collapse
Affiliation(s)
- Mariusz Tomaniak
- Department of Cardiology, Erasmus Medical Centre, Thorax Centre, Rotterdam, The Netherlands.,First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
| | - Yuki Katagiri
- Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - Rodrigo Modolo
- Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.,Cardiology Division, Department of Internal Medicine, University of Campinas (UNICAMP), Campinas, Brazil
| | - Ranil de Silva
- National Heart and Lung Institute, Imperial College London, London, UK.,NIHR Cardiovascular Biomedical Research Unit, Institute of Cardiovascular Medicine and Science, Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - Ramzi Y Khamis
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Christos V Bourantas
- Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London EC1A 7BE, UK.,William Harvey Research Institute, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, UK.,Institute of Cardiovascular Sciences, University College London, 62 Huntley St, Fitzrovia, London WC1E 6DD, UK
| | - Ryo Torii
- Department of Mechanical Engineering, University College London, Torrington Place, London WC1E 7JE, UK
| | - Jolanda J Wentzel
- Department of Cardiology, Biomedical Engineering, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Frank J H Gijsen
- Department of Biomedical Engineering, Erasmus Medical Centre, Thorax Centre, Rotterdam, The Netherlands
| | - Gijs van Soest
- Department of Cardiology, Biomedical Engineering, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - Peter H Stone
- Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Nick E J West
- Department of Interventional Cardiology, Royal Papworth Hospital, Papworth Rd, Trumpington, Cambridge CB2 0AY, UK
| | - Akiko Maehara
- Division of Cardiology, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA.,Clinical Trials Centre, Cardiovascular Research Foundation, New York, NY, USA
| | - Amir Lerman
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA
| | - Antonius F W van der Steen
- Department of Cardiology, Biomedical Engineering, Erasmus Medical Centre, Rotterdam, The Netherlands.,Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.,Department of Imaging Physics, Faculty of Applied Sciences, Delft University of Technology, Delft, The Netherlands
| | - Thomas F Lüscher
- Royal Brompton and Harefield Hospital Trust, Imperial College London, , London, UK.,Centre for Molecular Cardiology, University of Zurich, Zurich, Switzerland
| | | | - Wolfgang Koenig
- Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.,Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany
| | - Gregg W Stone
- Division of Cardiology, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA.,Clinical Trials Centre, Cardiovascular Research Foundation, New York, NY, USA
| | - James E Muller
- Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - William Wijns
- The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway, Ireland.,Saolta University Healthcare Group, Galway, Ireland
| | - Patrick W Serruys
- National Heart and Lung Institute, Imperial College London, London, UK.,Department of Cardiology, National University of Ireland, Galway, Ireland
| | - Yoshinobu Onuma
- Department of Cardiology, National University of Ireland, Galway, Ireland
| |
Collapse
|
29
|
Aetesam-Ur-Rahman M, Giblett JP, Khialani B, Kyranis S, Clarke SJ, Zhao TX, Braganza DM, Clarke SC, West NEJ, Bennett MR, Hoole SP. GLP-1 vasodilatation in humans with coronary artery disease is not adenosine mediated. BMC Cardiovasc Disord 2021; 21:223. [PMID: 33932990 PMCID: PMC8088691 DOI: 10.1186/s12872-021-02030-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Accepted: 04/21/2021] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Incretin therapies appear to provide cardioprotection and improve cardiovascular outcomes in patients with diabetes, but the mechanism of this effect remains elusive. We have previously shown that glucagon-like peptide (GLP)-1 is a coronary vasodilator and we sought to investigate if this is an adenosine-mediated effect. METHODS We recruited 41 patients having percutaneous coronary intervention (PCI) for stable angina and allocated them into four groups administering a specific study-related infusion following successful PCI: GLP-1 infusion (Group G) (n = 10); Placebo, normal saline infusion (Group P) (n = 11); GLP-1 + Theophylline infusion (Group GT) (n = 10); and Theophylline infusion (Group T) (n = 10). A pressure wire assessment of coronary distal pressure and flow velocity (thermodilution transit time-Tmn) at rest and hyperaemia was performed after PCI and repeated following the study infusion to derive basal and index of microvascular resistance (BMR and IMR). RESULTS There were no significant differences in the demographics of patients recruited to our study. Most of the patients were not diabetic. GLP-1 caused significant reduction of resting Tmn that was not attenuated by theophylline: mean delta Tmn (SD) group G - 0.23 s (0.27) versus group GT - 0.18 s (0.37), p = 0.65. Theophylline alone (group T) did not significantly alter resting flow velocity compared to group GT: delta Tmn in group T 0.04 s (0.15), p = 0.30. The resulting decrease in BMR observed in group G persisted in group GT: - 20.83 mmHg s (24.54 vs. - 21.20 mmHg s (30.41), p = 0.97. GLP-1 did not increase circulating adenosine levels in group GT more than group T: delta median adenosine - 2.0 ng/ml (- 117.1, 14.8) versus - 0.5 ng/ml (- 19.6, 9.4); p = 0.60. CONCLUSION The vasodilatory effect of GLP-1 is not abolished by theophylline and GLP-1 does not increase adenosine levels, indicating an adenosine-independent mechanism of GLP-1 coronary vasodilatation. TRIAL REGISTRATION The local research ethics committee approved the study (National Research Ethics Service-NRES Committee, East of England): REC reference 14/EE/0018. The study was performed according to institutional guidelines, was registered on http://www.clinicaltrials.gov (unique identifier: NCT03502083) and the study conformed to the principles outlined in the Declaration of Helsinki.
Collapse
Affiliation(s)
- Muhammad Aetesam-Ur-Rahman
- Department of Interventional Cardiology, Royal Papworth Hospital, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0AY, UK
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Joel P Giblett
- Department of Interventional Cardiology, Royal Papworth Hospital, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0AY, UK
| | - Bharat Khialani
- Department of Interventional Cardiology, Royal Papworth Hospital, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0AY, UK
| | - Stephen Kyranis
- Department of Interventional Cardiology, Royal Papworth Hospital, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0AY, UK
| | - Sophie J Clarke
- Department of Interventional Cardiology, Royal Papworth Hospital, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0AY, UK
| | - Tian X Zhao
- Department of Interventional Cardiology, Royal Papworth Hospital, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0AY, UK
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Denise M Braganza
- Department of Interventional Cardiology, Royal Papworth Hospital, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0AY, UK
| | - Sarah C Clarke
- Department of Interventional Cardiology, Royal Papworth Hospital, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0AY, UK
| | - Nick E J West
- Department of Interventional Cardiology, Royal Papworth Hospital, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0AY, UK
| | - Martin R Bennett
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Stephen P Hoole
- Department of Interventional Cardiology, Royal Papworth Hospital, Papworth Road, Cambridge Biomedical Campus, Cambridge, CB2 0AY, UK.
| |
Collapse
|
30
|
Onuma Y, Chevalier B, Ono M, Cequier À, Dudek D, Haude M, Carrié D, Sabaté M, Windecker S, Rapoza RR, West NEJ, Reith S, de Sousa Almeida M, Campo G, Íñiguez-Romo A, Serruys PW. Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial. EUROINTERVENTION 2020; 16:e938-e941. [PMID: 32515738 DOI: 10.4244/eij-d-20-00024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Yoshinobu Onuma
- Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
The global COVID-19 pandemic has led to unprecedented change throughout society.1 As the articles in this supplement outline, all segments of the broader cardiovascular community have been forced to adapt, to change models of care delivery, and to evolve and innovate in order to deliver optimal management for cardiovascular patients. The medtech/device industry has not been exempt from such change and has been forced to navigate direct and indirect COVID-associated disruption, with effects felt from supply chain logistics to the entire product lifecycle, from the running of clinical trials to new device approvals and managing training, proctoring and congresses in an increasingly-online world. This sea-change in circumstances itself has enforced the industry, in effect, to disrupt its own processes, models and activities. Whilst some of these changes may be temporary, many will endure for some time and some will doubtless become permanent; one thing is for sure: the healthcare ecosystem, including the medical device industry, will never look quite the same again. Although the pandemic has brought a short- to medium-term medical crisis to many countries, its role as a powerful disruptor cannot be underestimated, and may indeed prove to be a force for long-term good, given the accelerated innovation and rapid adaptation that it has cultivated.
Collapse
Affiliation(s)
- Nick E J West
- Abbott Vascular, 3200 Lakeside Drive, Santa Clara, CA 95054, USA
| | - Wai-Fung Cheong
- Abbott Structural Heart, 3200 Lakeside Drive, Santa Clara, CA 95054, USA
| | - Els Boone
- Abbott Vascular, 3200 Lakeside Drive, Santa Clara, CA 95054, USA
| | - Neil E Moat
- Abbott Structural Heart, 3200 Lakeside Drive, Santa Clara, CA 95054, USA
| |
Collapse
|
32
|
Clarke SJ, Giblett JP, Yang LL, Hubsch A, Zhao T, Aetesam-Ur-Rahman M, West NEJ, O'Sullivan M, Figg N, Bennett M, Wewer Albrechtsen NJ, Deacon CF, Cheriyan J, Hoole SP. GLP-1 Is a Coronary Artery Vasodilator in Humans. J Am Heart Assoc 2019; 7:e010321. [PMID: 30571482 PMCID: PMC6404441 DOI: 10.1161/jaha.118.010321] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Background The mechanism underlying the beneficial cardiovascular effects of the incretin GLP‐1 (glucagon‐like peptide 1) and its analogues in humans is elusive. We hypothesized that activating receptors located on vascular smooth muscle cells to induce either peripheral or coronary vasodilatation mediates the cardiovascular effect of GLP‐1. Methods and Results Ten stable patients with angina awaiting left anterior descending artery stenting underwent forearm blood flow measurement using forearm plethysmography and post–percutaneous coronary intervention coronary blood flow measurement using a pressure‐flow wire before and after peripheral GLP‐1 administration. Coronary sinus and artery bloods were sampled for GLP‐1 levels. A further 11 control patients received saline rather than GLP‐1 in the coronary blood flow protocol. GLP‐1 receptor (GLP‐1R) expression was assessed by immunohistochemistry using a specific GLP‐1R monoclonal antibody in human tissue to inform the physiological studies. There was no effect of GLP‐1 on absolute forearm blood flow or forearm blood flow ratio after GLP‐1, systemic hemodynamics were not affected, and no binding of GLP‐1R monoclonal antibody was detected in vascular tissue. GLP‐1 reduced resting coronary transit time (mean [SD], 0.87 [0.39] versus 0.63 [0.27] seconds; P=0.02) and basal microcirculatory resistance (mean [SD], 76.3 [37.9] versus 55.4 [30.4] mm Hg/s; P=0.02), whereas in controls, there was an increase in transit time (mean [SD], 0.48 [0.24] versus 0.83 [0.41] seconds; P<0.001) and basal microcirculatory resistance (mean [SD], 45.9 [34.7] versus 66.7 [37.2] mm Hg/s; P=0.02). GLP‐1R monoclonal antibody binding was confirmed in ventricular tissue but not in vascular tissue, and transmyocardial GLP‐1 extraction was observed. Conclusions GLP‐1 causes coronary microvascular dilation and increased flow but does not influence peripheral tone. GLP‐1R immunohistochemistry suggests that GLP‐1 coronary vasodilatation is indirectly mediated by ventricular‐coronary cross talk.
Collapse
Affiliation(s)
- Sophie J Clarke
- 1 Division of Cardiovascular Medicine University of Cambridge United Kingdom
| | - Joel P Giblett
- 3 Department of Interventional Cardiology Royal Papworth Hospital NHS Foundation Trust Cambridge United Kingdom
| | - Lucy L Yang
- 2 Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom
| | - Annette Hubsch
- 2 Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom
| | - Tian Zhao
- 3 Department of Interventional Cardiology Royal Papworth Hospital NHS Foundation Trust Cambridge United Kingdom
| | - Muhammad Aetesam-Ur-Rahman
- 3 Department of Interventional Cardiology Royal Papworth Hospital NHS Foundation Trust Cambridge United Kingdom
| | - Nick E J West
- 3 Department of Interventional Cardiology Royal Papworth Hospital NHS Foundation Trust Cambridge United Kingdom
| | - Michael O'Sullivan
- 3 Department of Interventional Cardiology Royal Papworth Hospital NHS Foundation Trust Cambridge United Kingdom
| | - Nichola Figg
- 1 Division of Cardiovascular Medicine University of Cambridge United Kingdom
| | - Martin Bennett
- 1 Division of Cardiovascular Medicine University of Cambridge United Kingdom
| | - Nicolai J Wewer Albrechtsen
- 4 Department of Biomedical Sciences NNF Centre for Basic Metabolic Research University of Copenhagen Denmark.,5 Department of Clinical Biochemistry, Rigshospitalet University of Copenhagen Denmark
| | - Carolyn F Deacon
- 4 Department of Biomedical Sciences NNF Centre for Basic Metabolic Research University of Copenhagen Denmark
| | - Joseph Cheriyan
- 2 Division of Experimental Medicine and Immunotherapeutics University of Cambridge United Kingdom
| | - Stephen P Hoole
- 3 Department of Interventional Cardiology Royal Papworth Hospital NHS Foundation Trust Cambridge United Kingdom
| |
Collapse
|
33
|
Giblett JP, Axell RG, White PA, Aetesam-Ur-Rahman M, Clarke SJ, Figg N, Bennett MR, West NEJ, Hoole SP. Glucagon-Like Peptide-1-Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon Occlusion. ACTA ACUST UNITED AC 2019; 4:222-233. [PMID: 31061924 PMCID: PMC6488814 DOI: 10.1016/j.jacbts.2018.12.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Revised: 12/07/2018] [Accepted: 12/10/2018] [Indexed: 11/28/2022]
Abstract
GLP-1 protects against ischemic left ventricular dysfunction after serial coronary balloon occlusion of the left anterior descending artery This study assessed whether serial right coronary artery balloon occlusion affected the right ventricle in a similar fashion using a conductance catheter method Serial balloon occlusion of the right coronary artery causes stunning and cumulative ischemic dysfunction in the right ventricle GLP-1 did not protect against stunning and cumulative ischemic dysfunction in the right ventricle
Stunning and cumulative ischemic dysfunction occur in the left ventricle with coronary balloon occlusion. Glucagon-like peptide (GLP)-1 protects the left ventricle against this dysfunction. This study used a conductance catheter method to evaluate whether the right ventricle (RV) developed similar dysfunction during right coronary artery balloon occlusion and whether GLP-1 was protective. In this study, the RV underwent significant stunning and cumulative ischemic dysfunction with right coronary artery balloon occlusion. However, GLP-1 did not protect the RV against this dysfunction when infused after balloon occlusion.
Collapse
Key Words
- BL, baseline
- BO1, first balloon occlusion
- BO2, second balloon occlusion
- DSHB, Developmental Studies Hybridoma Bank
- EDP, end-diastolic pressure
- GLP, glucagon-like peptide
- GLP-1R, glucagon-like peptide 1 receptor
- LV, left ventricular
- PCI, percutaneous coronary intervention
- PV, pressure–volume
- RCA, right coronary artery
- RV, right ventricular
- Tau, time constant of diastolic relaxation
- cardioprotection
- dP/dtmax, maximal rate of isovolumetric contraction
- dP/dtmin, maximal rate of isovolumetric relaxation
- glucagon-like peptide-1
- ischemia-reperfusion injury
- right ventricle
Collapse
Affiliation(s)
- Joel P Giblett
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, United Kingdom.,Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Richard G Axell
- Medical Physics and Clinical Engineering, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom
| | - Paul A White
- Medical Physics and Clinical Engineering, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom
| | - Muhammad Aetesam-Ur-Rahman
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, United Kingdom.,Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Sophie J Clarke
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Nicola Figg
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Martin R Bennett
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Nick E J West
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, United Kingdom
| | - Stephen P Hoole
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, United Kingdom.,Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom
| |
Collapse
|
34
|
Floré V, Brown AJ, Giblett JP, Liou K, Cranley J, Hoole SP, West NEJ. Clinical outcomes of bioresorbable vascular scaffolds implanted with routine versus selective optical coherence tomography guidance: results from a single-centre experience. EUROINTERVENTION 2019; 14:1776-1783. [PMID: 30375333 DOI: 10.4244/eij-d-18-00262] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
AIMS We aimed to investigate the effects of an initial learning period with mandatory optical coherence tomography (OCT) guidance for the implantation of everolimus-eluting bioresorbable vascular scaffolds (BVS). METHODS AND RESULTS We analysed procedural and clinical outcomes of all BVS implantations at a single centre where OCT guidance was mandatory in the initial rollout (OCT-mandatory) phase. We compared these data with the later phase where use of OCT was at operator discretion (OCT-selective or angiography). We implanted 406 BVS in 306 vessels (201 OCT, 105 angiography) in 272 patients. Follow-up duration was 38±10 months. Annualised rates of device-oriented cardiac events (DOCE) and scaffold thrombosis (ScT) were 1.4% and 0.4%, respectively. The risks of DOCE (HR 1.06, 95% CI: 0.33-3.34; p=0.71) and ScT (HR 0.48, 95% CI: 0.07-3.85; p=0.49) were not significantly different when comparing the OCT and angiography groups. CONCLUSIONS Routine use of OCT to guide and optimise BVS implants results in very acceptable outcomes. Further, the benefits of such an early OCT-mandatory "learning" period persist after cessation of routine OCT usage when imaging is not routinely used. A period of mandatory OCT usage for BVS implants may therefore be beneficial in improving patient outcomes with these devices.
Collapse
Affiliation(s)
- Vincent Floré
- Department of Interventional Cardiology, Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
35
|
Chang CC, Onuma Y, Achenbach S, Barbato E, Chevalier B, Cook S, Dudek D, Escaned J, Gori T, Kočka V, Tarantini G, West NEJ, Morice MC, Tijssen JGP, van Geuns RJ, Smits PC. Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial. Cardiovasc Revasc Med 2019; 20:577-582. [PMID: 31153846 DOI: 10.1016/j.carrev.2019.04.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Accepted: 04/11/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND The advent of bioresorbable vascular scaffolds (BVS) was considered as a potential improvement in percutaneous coronary intervention (PCI) after the groundbreaking development of drug eluting stents (DES). However, the clinical performance, long-term safety and efficacy of BVS in complex coronary lesions remain uncertain. COMPARE ABSORB, a multicenter, single blind, prospective randomized trial, aims to compare the clinical outcomes between the Absorb BVS and Xience everolimus-eluting metallic stent (EES) in patients with coronary artery disease and a high risk of restenosis. DESIGN COMPARE ABSORB is designed to enroll 2100 patients at up to 45 European sites. Enrolled patients will possess high risk for restenosis due to clinical profile or coronary lesion complexity and will undergo elective or emergent PCI. Once included in the study, patients will receive either Absorb BVS or Xience EES. Specific advice on implantation technique including mandatory pre-dilatation, sizing and post-dilatation (PSP), will be used in the Absorb BVS arm. The primary endpoint is target lesion failure (TLF), a device-oriented composite endpoint (cardiac death, target vessel myocardial infarction and clinically-indicated target lesion revascularization). The trial is powered to assess non-inferiority of Absorb BVS compared with Xience EES with a predetermined non-inferiority margin of 4.5% at 1 year after index procedure. The clinical follow-up will continue for 7 years. CONCLUSIONS The prospective COMPARE ABSORB randomized trial (ClinicalTrials.govNCT02486068) will help to assess the long-term safety and efficacy of Absorb BVS compared with Xience EES in the treatments of patients with complex coronary artery disease and a high attendant risk of restenosis.
Collapse
Affiliation(s)
- Chun Chin Chang
- Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taiwan
| | - Yoshinobu Onuma
- Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands; Cardialysis Clinical Trials Management and Core Laboratories, Rotterdam, the Netherlands
| | - Stephan Achenbach
- Department of Cardiology, Universitätsklinikum Erlangen, Erlangen, Germany
| | | | - Bernard Chevalier
- Ramsay Générale de Santé, ICPS, Hôpital Jacques Cartier, Massy, France
| | - Stéphane Cook
- Department of Cardiology, Hospital and University Fribourg, Switzerland
| | - Dariusz Dudek
- 2nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
| | - Javier Escaned
- Hospital Clinico San Carlos IDISSC, Complutense University, Madrid, Spain
| | - Tommaso Gori
- Center of Cardiology, Cardiology I, University Medical Center of the Johannes Gutenberg-University Mainz and DZHK Standort Rhein-Main, Mainz, Germany
| | - Viktor Kočka
- Third Faculty of Medicine, Charles University and University Hospital Královske Vinohrady, Prague, Czech Republic
| | - Giuseppe Tarantini
- Interventional Cardiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Italy
| | - Nick E J West
- Department of Interventional Cardiology, Royal Papworth Hospital, UK
| | | | - Jan G P Tijssen
- Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - Robert-Jan van Geuns
- Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands; Cardiology Department, Radboud UMC, Nijmegen, the Netherlands
| | - Pieter C Smits
- Cardiology Department, Maasstad Hospital, Rotterdam, the Netherlands.
| | | |
Collapse
|
36
|
Liou KP, Ooi SYM, Hoole SP, West NEJ. Fractional flow reserve in acute coronary syndrome: a meta-analysis and systematic review. Open Heart 2019; 6:e000934. [PMID: 30774965 PMCID: PMC6350698 DOI: 10.1136/openhrt-2018-000934] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Revised: 10/05/2018] [Accepted: 11/12/2018] [Indexed: 01/02/2023] Open
Abstract
Background The utility of fractional flow reserve (FFR) to guide revascularisation in the management of acute coronary syndrome (ACS) remains unclear. Objective This study aims to compare the clinical outcomes of patients following FFR-guided revascularisation for either ACS or stable angina (SA) and in particular focuses on the outcome of those with deferred revascularisation after FFR. Methods A meta-analysis of existing literature was performed. Outcomes including the rate of major adverse cardiovascular events (MACE), recurrent myocardial infarction (MI), mortality and unplanned revascularisation were analysed. Results A review of 937 records yielded 9 studies comparing 5457 patients, which were included in the analyses. Patients with ACS had a higher rate of recurrent MI (OR 1.81, p=0.02) and a strong trend towards more MACE and all-cause mortality compared with patients with SA when treated by an FFR-guided revascularisation strategy. Deferral of invasive therapy on the basis of FFR led to a higher rate of MACE (17.6% vs 7.3 %; p=0.004), recurrent MI (5.3% vs 1.5%, p=0.001) and target vessel revascularisation (16.4% vs 5.6 %; p=0.02) in patients with ACS, and a strong trend towards a higher cardiovascular mortality at follow-up when compared with patients with SA. Conclusion The event rate in patients with ACS is much higher than SA despite following an FFR-guided revascularisation strategy. Deferring revascularisation does not appear to be as safe for ACS as it is for SA using contemporary FFR cut-offs validated in SA. Refinement of the therapeutic strategy for patients with ACS with multivessel disease is needed to redress the balance.
Collapse
Affiliation(s)
- Kevin P Liou
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, UK.,Eastern Heart Clinic, Prince of Wales Hospital, Sydney, Australia.,Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
| | - Sze-Yuan M Ooi
- Eastern Heart Clinic, Prince of Wales Hospital, Sydney, Australia.,Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
| | - Stephen P Hoole
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, UK
| | - Nick E J West
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, UK
| |
Collapse
|
37
|
Nogic J, Thein P, Mirzaee S, Comella A, Soon K, Cameron JD, West NEJ, Brown AJ. Biodegradable-Polymer Versus Polymer-Free Drug-Eluting Stents for the Treatment of Coronary Artery Disease. Cardiovasc Revasc Med 2018; 20:865-870. [PMID: 30578169 DOI: 10.1016/j.carrev.2018.12.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 12/07/2018] [Accepted: 12/11/2018] [Indexed: 10/27/2022]
Abstract
BACKGROUND/PURPOSE Biodegradable-polymer (BP) and polymer-free (PF) drug eluting stents (DES) were developed to reduce the risk of delayed arterial healing observed with durable-polymer (DP) platforms. Although trials demonstrate BP-DES and PF-DES are non-inferior to DP-DES, there is limited data directly comparing these technologies. We performed a meta-analysis to assess the efficacy and safety of BP-DES versus PF-DES for the treatment of coronary artery disease. METHODS/MATERIALS Electronic searches were performed identifying randomized trials comparing BP-DES with PF-DES. Co-primary efficacy endpoints were target vessel revascularization (TVR), target lesion revascularization (TLR) and angiographic in-stent late lumen loss (LLL). Co-secondary safety endpoints were all-cause death, myocardial infarction (MI) and stent thrombosis (ST). RESULTS Of 208 studies, 5 met inclusion criteria including 1975 patients. At mean follow-up (14 ± 5 months), BP-DES were associated with significantly reduced rates of TVR (OR 0.58, 95%CI 0.37-0.92, p = 0.02), TLR (4.7% vs 9.5%) (OR 0.48, 95%CI 0.31-0.75, p = 0.001) and in-stent LLL (pooled mean difference -0.20 mm, 95%CI -0.24 to -0.16, p < 0.001). There was no difference in safety, including all-cause death (OR 1.24, 95%CI 0.68-2.28, p = 0.48), MI (OR 0.92, 95%CI 0.54-1.56, p = 0.75) or ST (OR 1.58, 95%CI 0.67-3.73, p = 0.30). CONCLUSIONS These data suggests that BP-DES are more efficacious when compared with PF-DES for the treatment of CAD.
Collapse
Affiliation(s)
- Jason Nogic
- Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Victoria, Australia
| | - Paul Thein
- Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Victoria, Australia
| | - Sam Mirzaee
- Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Victoria, Australia
| | - Andrea Comella
- Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Victoria, Australia
| | - Kean Soon
- Department of Cardiology, Eastern Health, Melbourne, Victoria, Australia
| | - James D Cameron
- Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Victoria, Australia
| | - Nick E J West
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, UK
| | - Adam J Brown
- Monash Cardiovascular Research Centre, Monash University and MonashHeart, Monash Health, Melbourne, Victoria, Australia.
| |
Collapse
|
38
|
Ha FJ, Nerlekar N, Cameron JD, Bennett MR, Meredith IT, West NEJ, Brown AJ. Midterm Safety and Efficacy of ABSORB Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent: An Updated Meta-Analysis. JACC Cardiovasc Interv 2018; 10:308-310. [PMID: 28183474 DOI: 10.1016/j.jcin.2016.11.054] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Accepted: 11/17/2016] [Indexed: 12/22/2022]
|
39
|
West NEJ, Corrigan JP, Brown AJ, Owen RHG, Hoole SP, Proudfoot D, Blatcher S. P32 LOCALISED CORONARY ARTERY INFLAMMATORY BIOMARKER EXPRESSION DOES NOT CORRELATE WITH SYSTEMIC ELEVATION OF BIOMARKERS OR hsCRP. Cardiovasc Res 2018. [DOI: 10.1093/cvr/cvy216.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Nick E J West
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge; PlaqueTec Ltd., Cambridge
- Department of Cardiovascular Medicine, University of Cambridge
| | - Joseph P Corrigan
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge; PlaqueTec Ltd., Cambridge
- Department of Cardiovascular Medicine, University of Cambridge
| | - Adam J Brown
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge; PlaqueTec Ltd., Cambridge
- Department of Cardiovascular Medicine, University of Cambridge
| | - Richard H G Owen
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge; PlaqueTec Ltd., Cambridge
- Department of Cardiovascular Medicine, University of Cambridge
| | - Stephen P Hoole
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge; PlaqueTec Ltd., Cambridge
- Department of Cardiovascular Medicine, University of Cambridge
| | - Diane Proudfoot
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge; PlaqueTec Ltd., Cambridge
- Department of Cardiovascular Medicine, University of Cambridge
| | - Stephen Blatcher
- Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge; PlaqueTec Ltd., Cambridge
- Department of Cardiovascular Medicine, University of Cambridge
| |
Collapse
|
40
|
Obaid DR, Calvert PA, Bennett MR, West NEJ. High-Risk Atherosclerotic Plaque in Aberrant Circumflex Coronary Artery. J Invasive Cardiol 2018; 30:E26. [PMID: 29493517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
A 45-year-old man presented after an episode of central chest pain. Catheter angiography revealed an aberrant circumflex artery and high-grade stenosis in the mid RCA and proximal CX arteries. Previous case series have suggested that the retroaortic portion of aberrant circumflex arteries may be particularly prone to the development of atherosclerosis.
Collapse
Affiliation(s)
- Daniel R Obaid
- Department of Cardiology, ABM University Health Board, Morriston Hospital, Swansea SA6 6NL, United Kingdom.
| | | | | | | |
Collapse
|
41
|
Baumbach A, Zaman A, West NEJ, O'Kane P, Egred M, Johnson T, Wheatcroft S, Bowles R, de Belder A, Bouras G, Lansky A, Hill J, Mathur A, de Belder MA, Banning AP. Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry. EUROINTERVENTION 2018; 13:1554-1560. [PMID: 29131802 DOI: 10.4244/eij-d-17-00886] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
AIMS The aim of this registry was to monitor practice patterns and outcomes in patients treated with Absorb bioresorbable vascular scaffolds (BVS) during the early phase of usage in the UK. METHODS AND RESULTS A total of 1,005 patients with de novo coronary lesions were treated using careful implantation techniques at 24 centres. Follow-up at one year was obtained in 99%. An independent clinical events committee and angiographic core lab adjudicated all events. Patient age was 52 years and 46% presented with acute coronary syndromes. Lesion complexity was B2/C in 47.4%, with an average of 1.4±0.6 BVS implanted and a BVS length of 28±14.3 mm. A single BVS was implanted in 71.3%. High pressure post-dilatation was performed in 94.9%, with 50% using intravascular imaging. Device success was achieved in 98.7% and procedure success in 97.3% of patients. At one year, the device-oriented endpoint target lesion failure was 3.2%, and the patient-oriented endpoint major adverse cardiac events was 3.4%. Definite ST occurred in 1.4%. By multivariable analysis, scaffold size of 2.5 mm predicted ST at one year (OR 3.27, 95% CI: 1.28-8.37; p=0.014). CONCLUSIONS With careful patient selection and technique, TLF rates following BVS implantation in real-world practice are comparable with contemporary drug-eluting stents. ST rates remain high, with small vessel size identified as a contributory factor.
Collapse
Affiliation(s)
- Andreas Baumbach
- Barts Heart Centre, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Floré V, Brown AJ, Pettit SJ, West NEJ, Lewis C, Parameshwar J, Hoole SP. Intravascular ultrasound of the proximal left anterior descending artery is sufficient to detect early cardiac allograft vasculopathy. Clin Transplant 2017; 32. [DOI: 10.1111/ctr.13167] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/23/2017] [Indexed: 11/27/2022]
Affiliation(s)
- Vincent Floré
- Department of Interventional Cardiology; Papworth Hospital; Cambridge UK
- Hartcentrum AZ Maria Middelares; Gent Belgium
| | - Adam J. Brown
- Department of Interventional Cardiology; Papworth Hospital; Cambridge UK
| | | | - Nick E. J. West
- Department of Interventional Cardiology; Papworth Hospital; Cambridge UK
| | - Clive Lewis
- Department of Transplantation; Papworth Hospital; Cambridge UK
| | | | - Stephen P. Hoole
- Department of Interventional Cardiology; Papworth Hospital; Cambridge UK
| |
Collapse
|
43
|
Costopoulos C, Huang Y, Brown AJ, Calvert PA, Hoole SP, West NEJ, Gillard JH, Teng Z, Bennett MR. Plaque Rupture in Coronary Atherosclerosis Is Associated With Increased Plaque Structural Stress. JACC Cardiovasc Imaging 2017; 10:1472-1483. [PMID: 28734911 PMCID: PMC5725311 DOI: 10.1016/j.jcmg.2017.04.017] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 02/21/2017] [Accepted: 04/05/2017] [Indexed: 11/22/2022]
Abstract
OBJECTIVES The aim of this study was to identify the determinants of plaque structural stress (PSS) and the relationship between PSS and plaques with rupture. BACKGROUND Plaque rupture is the most common cause of myocardial infarction, occurring particularly in higher risk lesions such as fibroatheromas. However, prospective intravascular ultrasound-virtual histology studies indicate that <10% higher risk plaques cause clinical events over 3 years, indicating that other factors also determine plaque rupture. Plaque rupture occurs when PSS exceeds its mechanical strength; however, the determinants of PSS and its association with plaques with proven rupture are not known. METHODS We analyzed plaque structure and composition in 4,053 virtual histology intravascular ultrasound frames from 32 fibroatheromas with rupture from the intravascular ultrasound-virtual histology in Vulnerable Atherosclerosis study and 32 fibroatheromas without rupture on optical coherence tomography from a stable angina cohort. Mechanical loading in the periluminal region was estimated by calculating maximum principal PSS by finite element analysis. RESULTS PSS increased with increasing lumen area (r = 0.46; p = 0.001), lumen eccentricity (r = 0.32; p = 0.001), and necrotic core ≥10% (r = 0.12; p = 0.001), but reduced when dense calcium was ≥10% (r = -0.12; p = 0.001). Ruptured fibroatheromas showed higher PSS (133 kPa [quartiles 1 to 3: 90 to 191 kPa] vs. 104 kPa [quartiles 1 to 3: 75 to 142 kPa]; p = 0.002) and variation in PSS (55 kPa [quartiles 1 to 3: 37 to 75 kPa] vs. 43 kPa [quartiles 1 to 3: 34 to 59 kPa]; p = 0.002) than nonruptured fibroatheromas, with rupture primarily occurring either proximal or immediately adjacent to the minimal luminal area (87.5% vs. 12.5%; p = 0.001). PSS was higher in segments proximal to the rupture site (143 kPa [quartiles 1 to 3: 101 to 200 kPa] vs. 120 kPa [quartiles 1 to 3: 78 to 180 kPa]; p = 0.001) versus distal segments, associated with increased necrotic core (19.1% [quartiles 1 to 3: 11% to 29%] vs. 14.3% [quartiles 1 to 3: 8% to 23%]; p = 0.001) but reduced fibrous/fibrofatty tissue (63.6% [quartiles 1 to 3: 46% to 78%] vs. 72.7% [quartiles 1 to 3: 54% to 86%]; p = 0.001). PSS >135 kPa was a good predictor of rupture in higher risk regions. CONCLUSIONS PSS is determined by plaque composition, plaque architecture, and lumen geometry. PSS and PSS variability are increased in plaques with rupture, particularly at proximal segments. Incorporating PSS into plaque assessment may improve identification of rupture-prone plaques.
Collapse
Affiliation(s)
- Charis Costopoulos
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Yuan Huang
- Department of Radiology, University of Cambridge, Cambridge, United Kingdom
| | - Adam J Brown
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom
| | - Patrick A Calvert
- Department of Interventional Cardiology, Papworth Hospital NHS Trust, United Kingdom
| | - Stephen P Hoole
- Department of Interventional Cardiology, Papworth Hospital NHS Trust, United Kingdom
| | - Nick E J West
- Department of Interventional Cardiology, Papworth Hospital NHS Trust, United Kingdom
| | - Jonathan H Gillard
- Department of Radiology, University of Cambridge, Cambridge, United Kingdom
| | - Zhongzhao Teng
- Department of Radiology, University of Cambridge, Cambridge, United Kingdom; Department of Engineering, University of Cambridge, Cambridge, United Kingdom.
| | - Martin R Bennett
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom.
| |
Collapse
|
44
|
Brown AJ, Shah ASV, West NEJ, Costopoulos C, Orzalkiewicz M, Newby DE, Bennett MR, Mills NL, Calvert PA. High-Sensitivity Troponin I Is Associated With High-Risk Plaque and MACE in Stable Coronary Artery Disease. JACC Cardiovasc Imaging 2017; 10:1200-1203. [PMID: 28109924 DOI: 10.1016/j.jcmg.2016.09.025] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Revised: 09/15/2016] [Accepted: 09/29/2016] [Indexed: 11/17/2022]
|
45
|
Obaid DR, Calvert PA, Brown A, Gopalan D, West NEJ, Rudd JHF, Bennett MR. Coronary CT angiography features of ruptured and high-risk atherosclerotic plaques: Correlation with intra-vascular ultrasound. J Cardiovasc Comput Tomogr 2017; 11:455-461. [PMID: 28918858 PMCID: PMC5725309 DOI: 10.1016/j.jcct.2017.09.001] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Revised: 08/10/2017] [Accepted: 09/03/2017] [Indexed: 11/19/2022]
Abstract
Background Features of ruptured and high-risk plaque have been described on coronary computed tomography angiography (coronary CTA), but not systematically assessed against intravascular ultrasound (IVUS). We examined the ability of coronary CTA to identify IVUS defined ruptured plaque and Virtual Histology Intravascular Ultrasound (VH-IVUS) defined thin-cap fibroatheroma (TCFA). Methods Sixty-three patients (32 with acute coronary syndrome and 31 with stable angina) underwent coronary CTA, IVUS and VH-IVUS. Plaque rupture on CTA was defined as intra-plaque contrast and its frequency compared with IVUS-defined plaque rupture. We then examined the relationship of conventional coronary CTA high-risk features (low attenuation plaque, positive remodeling, spotty calcification and the Napkin-Ring sign) in VH-IVUS-defined TCFA. We compared these with a novel index based on quantifying the ratio of necrotic core to fibrous plaque using x-ray attenuation cut-offs derived from the relationship of plaque to luminal contrast attenuation. Results Of the 71 plaques interrogated with IVUS, 39 were ruptured. Coronary CTA correctly detected 13-ruptured plaques with 3 false positives giving high specificity (91%) but low sensitivity (33%). None of the conventional coronary CTA high-risk features were significantly more frequent in the higher-risk (VH-IVUS defined thin-cap) compared with thick-cap fibroatheroma. However, the new index (necrotic core/fibrous plaque ratio) was higher in thin-cap (mean 0.90) vs. thick-cap fibroatheroma (mean 0.59), p < 0.05. Conclusions Compared with intravascular ultrasound, coronary CTA identifies ruptured plaque with good specificity but poor sensitivity. We have identified a novel high-risk feature on coronary CTA (necrotic core/fibrous plaque ratio that is associated with VH-IVUS defined-TCFA.
Collapse
Affiliation(s)
- Daniel R Obaid
- Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
| | - Patrick A Calvert
- Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
| | - Adam Brown
- Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
| | - Deepa Gopalan
- Department of Radiology, Papworth Hospital NHS Trust, Cambridge, UK
| | - Nick E J West
- Department of Interventional Cardiology, Papworth Hospital NHS Trust, Cambridge, UK
| | - James H F Rudd
- Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
| | - Martin R Bennett
- Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
| |
Collapse
|
46
|
Giblett JP, Brown AJ, Keevil H, Jaworski C, Hoole SP, West NEJ. Implantation of bioresorbable vascular scaffolds following acute coronary syndrome is associated with reduced early neointimal growth and strut coverage. EUROINTERVENTION 2017; 12:724-33. [PMID: 27542784 DOI: 10.4244/eijv12i6a117] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
AIMS Registry data have suggested higher than anticipated rates of scaffold thrombosis following bioresorbable vascular scaffold (BVS) implantation. We examined early neointimal growth and strut coverage in BVS to ascertain whether this was affected by clinical presentation. METHODS AND RESULTS Patients undergoing optical coherence tomography (OCT)-guided BVS implantation, either for stable angina (SA) or acute coronary syndrome (ACS), were recruited to this observational study. Repeat OCT was performed at follow-up (median 74 days), and scaffolds analysed at 1 mm longitudinal intervals for scaffold/flow area, scaffold apposition, neointimal growth and strut coverage. Twenty-nine BVS were included in the analysis (62% implanted following ACS). There were no differences in baseline patient/lesion characteristics. All BVS achieved >90% predicted scaffold area with only 1.64% of struts classified as incompletely apposed, compared with 0.47% at follow-up (p=0.006). Reductions in mean scaffold (-4.0%, p=0.01) and flow (-8.4%, p<0.001) areas were observed at follow-up, with larger reductions in mean flow area in stable patients (-14.5±14.2 vs. -4.9±7.9%, p=0.03). ACS patients had reduced neointimal growth (0.51±0.18 vs. 0.87±0.37 mm2, p=0.002), and increased percentage of uncovered struts (2.68±1.67 vs. 1.43±0.87%, p=0.015). CONCLUSIONS Early neointimal growth and strut coverage are reduced following ACS in patients receiving BVS. These results may, in part, explain the high rates of ST in registry data.
Collapse
Affiliation(s)
- Joel P Giblett
- Department of Interventional Cardiology, Papworth Hospital, Cambridge, United Kingdom
| | | | | | | | | | | |
Collapse
|
47
|
Axell RG, Giblett JP, White PA, Klein A, Hampton-Til J, O'Sullivan M, Braganza D, Davies WR, West NEJ, Densem CG, Hoole SP. Stunning and Right Ventricular Dysfunction Is Induced by Coronary Balloon Occlusion and Rapid Pacing in Humans: Insights From Right Ventricular Conductance Catheter Studies. J Am Heart Assoc 2017; 6:JAHA.117.005820. [PMID: 28588092 PMCID: PMC5669185 DOI: 10.1161/jaha.117.005820] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Background We sought to determine whether right ventricular stunning could be detected after supply (during coronary balloon occlusion [BO]) and supply/demand ischemia (induced by rapid pacing [RP] during transcatheter aortic valve replacement) in humans. Methods and Results Ten subjects with single‐vessel right coronary artery disease undergoing percutaneous coronary intervention with normal ventricular function were studied in the BO group. Ten subjects undergoing transfemoral transcatheter aortic valve replacement were studied in the RP group. In both, a conductance catheter was placed into the right ventricle, and pressure volume loops were recorded at baseline and for intervals over 15 minutes after a low‐pressure BO for 1 minute or a cumulative duration of RP for up to 1 minute. Ischemia‐induced diastolic dysfunction was seen 1 minute after RP (end‐diastolic pressure [mm Hg]: 8.1±4.2 versus 12.1±4.1, P<0.001) and BO (end‐diastolic pressure [mm Hg]: 8.1±4.0 versus 8.7±4.0, P=0.03). Impairment of systolic and diastolic function after BO remained at 15‐minutes recovery (ejection fraction [%]: 55.7±9.0 versus 47.8±6.3, P<0.01; end‐diastolic pressure [mm Hg]: 8.1±4.0 versus 9.2±3.9, P<0.01). Persistent diastolic dysfunction was also evident in the RP group at 15‐minutes recovery (end‐diastolic pressure [mm Hg]: 8.1±4.1 versus 9.9±4.4, P=0.03) and there was also sustained impairment of load‐independent indices of systolic function at 15 minutes after RP (end‐systolic elastance and ventriculo‐arterial coupling [mm Hg/mL]: 1.25±0.31 versus 0.85±0.43, P<0.01). Conclusions RP and right coronary artery balloon occlusion both cause ischemic right ventricular dysfunction with stunning observed later during the procedure. This may have intraoperative implications in patients without right ventricular functional reserve.
Collapse
Affiliation(s)
- Richard G Axell
- Medical Physics and Clinical Engineering, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom.,Postgraduate Medical Institute, Anglia Ruskin University, Chelmsford, United Kingdom
| | - Joel P Giblett
- Department of Interventional Cardiology, Papworth Hospital, Cambridge, United Kingdom.,Division of Cardiovascular Medicine, University of Cambridge, United Kingdom
| | - Paul A White
- Medical Physics and Clinical Engineering, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom.,Postgraduate Medical Institute, Anglia Ruskin University, Chelmsford, United Kingdom
| | - Andrew Klein
- Department of Interventional Cardiology, Papworth Hospital, Cambridge, United Kingdom
| | - James Hampton-Til
- Postgraduate Medical Institute, Anglia Ruskin University, Chelmsford, United Kingdom
| | - Michael O'Sullivan
- Department of Interventional Cardiology, Papworth Hospital, Cambridge, United Kingdom
| | - Denise Braganza
- Department of Interventional Cardiology, Papworth Hospital, Cambridge, United Kingdom
| | - William R Davies
- Department of Interventional Cardiology, Papworth Hospital, Cambridge, United Kingdom
| | - Nick E J West
- Department of Interventional Cardiology, Papworth Hospital, Cambridge, United Kingdom
| | - Cameron G Densem
- Department of Interventional Cardiology, Papworth Hospital, Cambridge, United Kingdom
| | - Stephen P Hoole
- Department of Interventional Cardiology, Papworth Hospital, Cambridge, United Kingdom
| |
Collapse
|
48
|
Brown AJ, Teng Z, Calvert PA, Rajani NK, Hennessy O, Nerlekar N, Obaid DR, Costopoulos C, Huang Y, Hoole SP, Goddard M, West NEJ, Gillard JH, Bennett MR. Plaque Structural Stress Estimations Improve Prediction of Future Major Adverse Cardiovascular Events After Intracoronary Imaging. Circ Cardiovasc Imaging 2017; 9:CIRCIMAGING.115.004172. [PMID: 27307548 DOI: 10.1161/circimaging.115.004172] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 05/09/2016] [Indexed: 11/16/2022]
Abstract
BACKGROUND Although plaque rupture is responsible for most myocardial infarctions, few high-risk plaques identified by intracoronary imaging actually result in future major adverse cardiovascular events (MACE). Nonimaging markers of individual plaque behavior are therefore required. Rupture occurs when plaque structural stress (PSS) exceeds material strength. We therefore assessed whether PSS could predict future MACE in high-risk nonculprit lesions identified on virtual-histology intravascular ultrasound. METHODS AND RESULTS Baseline nonculprit lesion features associated with MACE during long-term follow-up (median: 1115 days) were determined in 170 patients undergoing 3-vessel virtual-histology intravascular ultrasound. MACE was associated with plaque burden ≥70% (hazard ratio: 8.6; 95% confidence interval, 2.5-30.6; P<0.001) and minimal luminal area ≤4 mm(2) (hazard ratio: 6.6; 95% confidence interval, 2.1-20.1; P=0.036), although absolute event rates for high-risk lesions remained <10%. PSS derived from virtual-histology intravascular ultrasound was subsequently estimated in nonculprit lesions responsible for MACE (n=22) versus matched control lesions (n=22). PSS showed marked heterogeneity across and between similar lesions but was significantly increased in MACE lesions at high-risk regions, including plaque burden ≥70% (13.9±11.5 versus 10.2±4.7; P<0.001) and thin-cap fibroatheroma (14.0±8.9 versus 11.6±4.5; P=0.02). Furthermore, PSS improved the ability of virtual-histology intravascular ultrasound to predict MACE in plaques with plaque burden ≥70% (adjusted log-rank, P=0.003) and minimal luminal area ≤4 mm(2) (P=0.002). Plaques responsible for MACE had larger superficial calcium inclusions, which acted to increase PSS (P<0.05). CONCLUSIONS Baseline PSS is increased in plaques responsible for MACE and improves the ability of intracoronary imaging to predict events. Biomechanical modeling may complement plaque imaging for risk stratification of coronary nonculprit lesions.
Collapse
Affiliation(s)
- Adam J Brown
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Zhongzhao Teng
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Patrick A Calvert
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Nikil K Rajani
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Orla Hennessy
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Nitesh Nerlekar
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Daniel R Obaid
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Charis Costopoulos
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Yuan Huang
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Stephen P Hoole
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Martin Goddard
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Nick E J West
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Jonathan H Gillard
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom
| | - Martin R Bennett
- From the Division of Cardiovascular Medicine (A.J.B., P.A.C., N.K.R., O.H., D.R.O., C.C., M.R.B.), Department of Radiology (Z.T., Y.H., J.H.G.), and Department of Engineering (Z.T.), University of Cambridge, United Kingdom; MonashHEART, Monash Medical Centre, Clayton, Australia (N.N.); and Department of Interventional Cardiology (P.A.C., S.P.H., N.E.J.W.) and Department of Pathology (M.G.), Papworth Hospital NHS Trust, United Kingdom.
| |
Collapse
|
49
|
Giblett JP, Brown AJ, Hoole SP, West NEJ. Early disarticulation of a bioresorbable vascular scaffold: an underreported consequence of repeat imaging. Cardiovasc Interv Ther 2017; 33:175-177. [DOI: 10.1007/s12928-017-0464-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Accepted: 02/24/2017] [Indexed: 10/20/2022]
|
50
|
Giblett JP, Axell RG, White PA, Clarke SJ, McCormick L, Read PA, Reinhold J, Brown AJ, O'Sullivan M, West NEJ, Dutka DP, Hoole SP. Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies. Cardiovasc Diabetol 2016; 15:99. [PMID: 27431258 PMCID: PMC4950774 DOI: 10.1186/s12933-016-0416-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2016] [Accepted: 06/30/2016] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Glucagon-like peptide-1 (7-36) amide (GLP-1) protects against stunning and cumulative left ventricular dysfunction in humans. The mechanism remains uncertain but GLP-1 may act by opening mitochondrial K-ATP channels in a similar fashion to ischemic conditioning. We investigated whether blockade of K-ATP channels with glibenclamide abrogated the protective effect of GLP-1 in humans. METHODS Thirty-two non-diabetic patients awaiting stenting of the left anterior descending artery (LAD) were allocated into 4 groups (control, glibenclamide, GLP-1, and GLP-1 + glibenclamide). Glibenclamide was given orally prior to the procedure. A left ventricular conductance catheter recorded pressure-volume loops during a 1-min low-pressure balloon occlusion (BO1) of the LAD. GLP-1 or saline was then infused for 30-min followed by a further 1-min balloon occlusion (BO2). In a non-invasive study, 10 non-diabetic patients were randomized to receive two dobutamine stress echocardiograms (DSE) during GLP-1 infusion with or without oral glibenclamide pretreatment. RESULTS GLP-1 prevented stunning even with glibenclamide pretreatment; the Δ % dP/dtmax 30-min post-BO1 normalized to baseline after GLP-1: 0.3 ± 6.8 % (p = 0.02) and GLP-1 + glibenclamide: -0.8 ± 9.0 % (p = 0.04) compared to control: -11.5 ± 10.0 %. GLP-1 also reduced cumulative stunning after BO2: -12.8 ± 10.5 % (p = 0.02) as did GLP-1 + glibenclamide: -14.9 ± 9.2 % (p = 0.02) compared to control: -25.7 ± 9.6 %. Glibenclamide alone was no different to control. Glibenclamide pretreatment did not affect global or regional systolic function after GLP-1 at peak DSE stress (EF 74.6 ± 6.4 vs. 74.0 ± 8.0, p = 0.76) or recovery (EF 61.9 ± 5.7 vs. 61.4 ± 5.6, p = 0.74). CONCLUSIONS Glibenclamide pretreatment does not abrogate the protective effect of GLP-1 in human models of non-lethal myocardial ischemia. Trial registration Clinicaltrials.gov Unique Identifier: NCT02128022.
Collapse
Affiliation(s)
- Joel P Giblett
- Department of Interventional Cardiology, Papworth Hospital, Papworth Everard, Cambridge, CB23 3RE, UK.,Department of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Richard G Axell
- Department of Clinical Engineering, Addenbrooke's Hospital, Cambridge, UK
| | - Paul A White
- Department of Clinical Engineering, Addenbrooke's Hospital, Cambridge, UK
| | - Sophie J Clarke
- Department of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Liam McCormick
- Department of Interventional Cardiology, Papworth Hospital, Papworth Everard, Cambridge, CB23 3RE, UK
| | - Philip A Read
- Department of Interventional Cardiology, Papworth Hospital, Papworth Everard, Cambridge, CB23 3RE, UK
| | - Johannes Reinhold
- Department of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Adam J Brown
- Department of Interventional Cardiology, Papworth Hospital, Papworth Everard, Cambridge, CB23 3RE, UK.,Department of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Michael O'Sullivan
- Department of Interventional Cardiology, Papworth Hospital, Papworth Everard, Cambridge, CB23 3RE, UK
| | - Nick E J West
- Department of Interventional Cardiology, Papworth Hospital, Papworth Everard, Cambridge, CB23 3RE, UK
| | - David P Dutka
- Department of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Stephen P Hoole
- Department of Interventional Cardiology, Papworth Hospital, Papworth Everard, Cambridge, CB23 3RE, UK.
| |
Collapse
|